

Session Title: #167: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Highlights of the Day

Date: Sunday, June 6

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

Everett E. Vokes, MD

- Clinical Trials Participation Awards

Douglas W. Blayney, MD

- Discussion: Lymphoma and Plasma Cell Disorders

Bruce D. Cheson, MD

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy

Alan B Sandler, MD

- Discussion: Patient and Survivor Care

Gretchen Genevieve Kimmick, MD

- Discussion: Melanoma/Skin Cancers

F. Stephen Hodi, MD

Session Title: #11: Allogeneic Transplantation Advances and Controversies

Session Type: Education Session

Date: Sunday, June 6

Location: E354b

Time: 8:00 AM - 9:15 AM

- Advances in Alternative Donor Transplant

Koen van Besien, MD

- Reduced intensity, myeloablative and transplant lite. What's in a name?

Parameswaran Hari, MD, MRCP, MS

- Transplant for Acute Myeloid Leukemia: Who should be transplanted in CR1?

Marcos J.G. De Lima, MD

Session Title: #21: Caregiving to Elderly Patients: Clinical, Ethical, and Psychosocial Challenges

Session Type: Education Session

Date: Sunday, June 6

Location: S100a

Time: 8:00 AM - 9:15 AM

- Ethical and social implications of caregiving to elderly cancer patients

Antonella Surbone, MD, PhD, FACP

- Beyond the possible: appraising the needs of elderly cancer patients' caregivers

Lea Baidar, PhD

- The spirituality of the home caregiver

Lodovico Balducci, MD

Session Title: #30: Controversies in the Management of Colorectal Cancer

Session Type: Education Session

Date: Sunday, June 6

Location: N Hall B1

Time: 8:00 AM - 9:15 AM

- Is there an optimal treatment strategy for advanced colorectal cancer?

Axel Grothey, MD

- Treatment of colorectal cancer with peritoneal carcinomatosis - knife, drugs, or both?

David L. Bartlett, MD

- Neoadjuvant therapy of rectal cancer - how can we make it better?

Claus Roedel, MD

Session Title: #31: Controversies in the Management of Desmoid Tumors

Session Type: Education Session

Date: Sunday, June 6

Location: S406 (Vista Room)

Time: 8:00 AM - 9:15 AM

- Local management of desmoid tumors
Murray F. Brennan, MD
- Non-operative management of desmoids with or without systemic therapy
Sylvie Bonvalot, MD, PhD
- Molecular Markers of Desmoid recurrence
Alexander Lazar, MD, PhD

Session Title: #56: HPV Status and Clinical Decision-making for Patients with Oropharynx Cancer

Session Type: Education Session

Date: Sunday, June 6

Location: E Hall D2

Time: 8:00 AM - 9:15 AM

- Clinical Implications of Human Papillomavirus-etiology of Head and Neck Cancers: An Update
Maura L. Gillison, MD, PhD
- The Development of Prospective HPV-specific Head and Neck Cancer Clinical Trials
Andy Trotti, MD
- Biological Correlates of HPV Tumor Status
Lisa F. Licitra, MD

Session Title: #84: Optimal Treatment for Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Session Type: Education Session

Date: Sunday, June 6

Location: S504

Time: 8:00 AM - 9:15 AM

- New insights into the biological basis of ALL

- Converging approaches to treating childhood, adolescent and young adult ALL

Stephen Hunger, MD

Session Title: #86: PARP Inhibitors and More in DNA Repair

Session Type: Education Session

Date: Sunday, June 6

Location: E353

Time: 8:00 AM - 9:15 AM

- DNA Repair - Nuts & Bolts

James M. Ford, MD

- PARP inhibitors' function and opportunities for combination therapy

Nicola J Curtin, PhD

- DNA repair defect in BRCA mutant cells- a new therapeutic road

Thomas Helleday, PhD

Session Title: #101: The Global Status of HPV Vaccination

Session Type: Education Session

Date: Sunday, June 6

Location: S100b

Time: 8:00 AM - 9:15 AM

- Long-term efficacy of prophylactic monovalent HPV vaccines in developing countries

Laura A. Koutsky, PhD, MSPH

- Barriers to the introduction of HPV vaccines into the developing world: should boys be vaccinated?

Mark A. Kane, MD, MPH

- HPV vaccines for the developing world: review and new approaches to broaden HPV coverage and reduce vaccination costs

Patti Gravitt, MS, PhD

Session Title: #115: Controversies in Stage IIIA Non-small Cell Lung Cancer

Session Type: Meet the Professor Session

Date: Sunday, June 6

Location: E451b

Time: 8:00 AM - 9:15 AM

- Controversies in Stage IIIA NSCLC

Renato Martins, MD, MPH

Session Title: #121: Forum on Reimbursement

Session Type: Special Session

Date: Sunday, June 6

Location: E Arie Crown Theater

Time: 8:00 AM - 9:15 AM

- Forum on Reimbursement

Steven Stranne, MD, JD

- Forum on Reimbursement

Joseph S. Bailes, MD

Session Title: #130: Immunosuppression in Patients with Lymphoma and Myeloma

Session Type: Clinical Problems in Oncology Session

Date: Sunday, June 6

Location: E451a

Time: 8:00 AM - 9:15 AM

- Prolonged B-cell Suppression from anti-CD20 therapies: What are the risks?

Myron Stefan Czuczman, MD

- Impact of T-cell Directed Therapies on Immunocompetence

Francine M. Foss, MD

- Prevention, Surveillance and Management of Viral Reactivation in the setting of Immunosuppressive Therapies for Lymphoma and Myeloma

John A. Zaia, MD

Session Title: #196: Central Nervous System Tumors**Session Type:** General Poster Session**Date:** Sunday, June 6**Location:** S Hall A2**Time:** 8:00 AM - 12:00 PM

1A #2033-Predictive impact of *IDH1* or *IDH2* mutations on outcome and response to temozolomide in low-grade gliomas.

Caroline Houillier

1B #2034-Prognostic factors for glioblastoma (GBM) in individuals age 70 and older: A study of 446 patients from two tertiary centers.

Jacob G Scott

1C #2035-Prognostic and predictive markers in recurrent high-grade glioma (HGG): Results from the BR12 randomized trial.

Michael Brada, MD

1D #2036-Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).

Antonio Marcilio Padula Omuro

1E #2037-Acute neurological toxicity (NT) and long-term outcomes in high-grade glioma RTOG trials.

Yaacov Richard Lawrence

1F #2038-Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG).

Alise Brickhouse

1G #2039-Open-label, dose confirmation, and dosimetry study of interstitial ¹³¹I-chTNT-1/B MAb for the treatment of recurrent glioblastoma multiforme (GBM): Final results.

William R. Shapiro

1H #2040-Methotrexate (M) area under the curve (AUC) and creatinine clearance (CrCl) as prognostic factors in primary central nervous system lymphoma (PCNSL).

Patrick Glyn Morris

2A #2041-Quality-of-life concordance between patients with malignant gliomas (MG) and their caregivers.

Daniel Jacobs

2B #2042-¹⁸F-FET-PET hypermetabolic brain lesions: A correlation study to MRI and histopathologic findings.

Armin Muigg

2C #2043-Safety of concurrent bevacizumab therapy and anticoagulation in

2D #2044-Interim analysis of the randomized PATSGO trial evaluating the prolongation of adjuvant temozolomide in newly diagnosed glioblastoma patients.

Jean-Francois Baurain

2E #2045-Long-term survival from the initial trial of bevacizumab and irinotecan.

Annick Desjardins

2F #2046-Secondary hematologic malignancies associated with temozolomide (TMZ) in patients with glioma.

Hiroyuki Momota

2G #2047-Influence of vascular endothelial growth factor (VEGF) single nucleotide polymorphisms (SNPs) on prognosis of glioblastoma (GB) patients.

Claude Linassier

2H #2048-Radiotherapy with or without temozolomide in elderly glioblastoma patients: Treatment results and prognostic factors.

Ahmet Dirier

3A #2049-A mesenchymal/stem cell predictor of survival of patients with malignant gliomas.

Erik P. Sulman, MD, PhD

3B #2050-Phase II and pharmacogenomics study of enzastaurin plus temozolomide and radiation in patients with GBM.

Nicholas A. Butowski

3C #2051-Use of functional protein pathway activation mapping in glioblastoma samples to differentiate long-term from short-term survivors along with pathway-driven molecular subgroups.

Claudius Mueller

3D #2052-Expression of endoglin CD105 and nestin to assess neoangiogenesis in peritumor tissue of glioblastoma.

Gigliola Sica (1)

3E #2053-MGMT promoter methylation and *IDH1* mutation as prognostic markers for a favorable clinical outcome in patients with glioblastoma multiforme.

Agnieszka Wozniak

3F #2054-Pseudoprogression after treatment with the TGF-beta 2 inhibitor trabedersen in high-grade glioma patients.

Ulrich Bogdahn

3G #2055-Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results.

Sith Sathornsumetee

3H #2056-Current status of phase III anti-EGF-receptor antibody (OSAG-101) for newly diagnosed glioblastoma.

Manfred Westphal

4A #2057-Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.

Tobias Walbert

4B #2058-Whole-brain radiotherapy with concurrent fixed-dose daily temozolomide for brain metastases treatment: A randomized phase II trial.

Carlos Gamboa-Vignolle, MD

4C #2059-Use of bevacizumab to facilitate up-front chemoradiation in poor-risk patients with glioblastoma multiforme by improving neurologic function.

Richard M. Green

4D #2060-Imatinib mesylate plus hydroxyurea for adults with recurrent/progressive low-grade glioma: Final phase II study results.

Katherine Peters

4E #2061-Evaluation of three stratification systems predicting recurrence and prognosis in patients with brain metastases after tumor removal and whole-brain irradiation.

Victor Lee

4F #2062-Determinants of therapeutic resistance in glioblastomas: Lessons learned from RTOG 0211 and beyond.

Arnab Chakravarti

4G #2063-Use of FLAIR MRI in determining glioblastoma response to cediranib.

Elizabeth Robins Gerstner

4H #2064-Evaluation of distant spread in bevacizumab-treated versus control-treated patients with malignant gliomas: A matched-pair study.

Michael Platten

5A #2065-Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV).

Mustafa Khasraw

5B #2066^--A prospective study of surgery plus biodegradable carmustine wafers for local control and neurocognitive function in 39 patients with one to three brain metastases: Preliminary results.

Steven Brem

5C #2067-Levels of circulating endothelial cells in relapsing glioblastoma patients responding to bevacizumab.

Marica Eoli

5D #2068-A prospective trial on the efficacy of a multiparametric imaging biomarker for early identification of GBM patients resistant to first-line therapy.

Craig J Galbán

5E #2069-Phase I/IIa trial of autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.

Yoshihiro Muragaki

5F #2070-Temozolomide and radiation therapy in elderly patients affected by glioblastomas: A pooled analyses of three prospective phase II trials.

Alba Fiorentino

5G #2071-High-dose radiation therapy using photons and carbon ion radiotherapy in patients with atypical and anaplastic meningiomas: Relevance of neuropathologic classification and therapeutic impact of a boost using of carbon ion radiotherapy.

Stephanie E. Combs

5H #2072-Phase II trial of combined temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy.

Sumitra Ananda

6A #2073-Phase I trial of the addition of oral topotecan to standard 5-day temozolomide for malignant gliomas.

John Kirkpatrick

6B #2074-Prospective validation of the new graded prognostic assessment scale for brain metastases: A multicenter study.

Salvador Villa

6C #2075-Phase II trial of radiation therapy/temozolomide/bevacizumab followed by bevacizumab/everolimus in the first-line treatment of glioblastoma multiforme (GBM).

Kent C. Shih

6D #2076-MGMT promoter methylation status and DNA mismatch repair genes in paired primary and recurrent glioblastoma: A translational study of the German Glioma Network.

Joerg Christian Tonn

6E #2077-Preoperative blood parameters as biomarkers for high-grade gliomas.

Mark Rosenthal

6F #2078-Longitudinal analysis of physiologic MRI parameters in patients with newly diagnosed glioblastoma multiforme to predict outcome.

Yan LI

6G #2079-Characterization of pseudoprogression in patients with glioblastoma: Is histology the gold standard?

Isaac Melguizo

6H #2080-Quality of life in patients with pure and mixed anaplastic oligodendroglioma treated with dose-intense temozolomide: A phase II multicenter study.

Nooshin Hashemi Sadraei

7A #2081-Accuracy of a modeling algorithm to optimize perfusion MRI detection of glioma recurrence.

Leland S Hu

7B #2082-Preclinical evaluation of bafetinib for treatment of glioblastoma multiforme.

Vamsidhar Velcheti

7C #2083-Phase I/II study of vandetanib for patients with recurrent malignant gliomas.

Katharine Anne Mcnicol

7D #2084-Correlation of cognitive symptoms with cognitive performance among brain cancer patients after radiation therapy.

Stephen R. Rapp

7E #2085-A new gene expression-based diagnostic test to predict prognosis of gliomas for the support of histopathologic diagnosis.

Kikuya Kato

7F #2086-Circulating endothelial cells, microparticles, and markers of inflammation and coagulation in glioblastoma patients before and after protracted temozolomide and radiotherapy.

Gaspar Reynes

7G #2087-Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in recurrent malignant glioma (MG).

Alexandra Benouaich-Amiel

8A #2089-CYP3A-inducing antiepileptics decrease sorafenib exposures: Results of a phase II study in adults with recurrent glioblastoma.

Sridharan Gururangan

8B #2090-Assessment of diffusion parameters in scans prior to progression in GBM patients following antiangiogenic therapy.

Laleh Jalilian

8C #2091-Study of quality of life in brain tumor patients treated with three-dimensional conformal radiotherapy.

Vankamamidi Venkata Sampath, MBBS

8D #2092-Using a prospective comprehensive database to define features that impact the outcome of patients with glioblastoma multiforme.

Kathryn Maree Field

8E #2093-Comparison of intratumoral loading of Flt3L/TK-recruited dendritic cells and systemic vaccination with tumor-lysate loaded dendritic cells in the stringent syngeneic CNS1 rat glioma model: Effect of temozolomide on anti-glioma immunity.

Pedro R. Lowenstein

8F #2094-A phase II trial of TLN-4601 in patients with glioblastoma multiforme (GBM) at first progression.

Warren P. Mason

8G #2095-A clinical study investigating MPC-6827 with carboplatin in the treatment of patients with relapsed glioblastoma multiforme.

Kenneth F. Grossmann

9A #2097-Immune response correlation with progression-free survival in glioblastoma following dendritic cell immunotherapy (ICT-107).

Surasak Phuphanich

9B #2098-New therapeutic approach for brain tumors: Intranasal administration of Ras inhibitor perillyl alcohol.

Clovis O Fonseca

Session Title: #203: Head and Neck Cancer

Session Type: General Poster Session

Date: Sunday, June 6

Location: S Hall A2

Time: 8:00 AM - 12:00 PM

10A #5537-Tumor molecular correlates of unresectable, locally advanced head and neck squamous cell carcinoma (SCCHN) response to concurrent radiation (RT), cisplatin (DDP), and cetuximab (C225) in a phase II trial (ECOG 3303).

Ann Marie Egloff

10B #5538-Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (HNSCC) using AQUA.

Eirini Pectasides

10C #5539-Analysis of ERCC1 (excision repair cross complementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297.

Ranee Mehra, MD

10D #5540-ERCC1 protein, mRNA expression, and T19007C polymorphism as prognostic markers in head and neck squamous cell carcinoma (HNSCC) patients treated with surgery and adjuvant cisplatin-based chemoradiation (CRT).

Gilberto Castro

10E #5541-Expression and prognostic significance of x-ray crosscomplementation group 1 (XRCC1) in head and neck squamous cell carcinoma patients undergoing concurrent chemoradiation.

Mei-Kim Ang

10F #5542-Use of angiopoietin-1 expression in squamous cell carcinoma of the head and neck to predict disease-free survival.

Muthuswamy Dhiwakar

10G #5543-Correlation of expression of haptoglobin and recurrence in head and neck squamous cell cancer.

Yu-Chieh Su, MD, MSc

10H #5544-Outcomes in HPV-associated oropharyngeal squamous cell carcinoma after postoperative or definitive nonsurgical therapy.

Christopher R. Spencer

11A #5545-Detection of antibodies to the HPV16 proteome in head and neck cancer patient sera.

Karen S. Anderson

11B #5546-Prognosis of HPV-positive squamous cell carcinoma of tonsil-expressing high level of p16 and low level of EGFR.

Hye Sung Won

11F #5547-Use of T-cell infiltrate to predict long-term survival following local therapy in tongue cancer patients.

Jung Sun Kim, BM, BCh, MSc

11G #5548-Prognostic value of biomarkers in tissue microarrays (TMAs) of squamous cell carcinomas of the oral tongue (SCCOT).

William Nassib William Junior

11H #5549-Evaluation of ALDH1-A1 as a biomarker for metastasis of head and neck cancer.

Zhuo Georgia Chen

12A #5550-The prognostic value of STAT3 protein in patients with head and neck squamous cell carcinoma (HNSCC) harboring PTEN loss.

George Fountzilas

12B #5551-Expression of drug-resistance-related proteins in nasopharyngeal cancer (NPC) patients treated with cisplatin-based concurrent chemoradiotherapy.

Hyun Woo Lee, MD

12F #5552-Association of high Gli1 expression with poor survival in head and neck cancer patients treated with radiation therapy (RTOG 9003).

Christine H. Chung

12G #5553-Prospective phase II study of tumor response assessment by CT and FDG-PET/CT following 8 weekly doses of cetuximab in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).

Jessica Ley

12H #5554-A phase II study of pemetrexed (P) plus gemcitabine (G) in patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC).

David G. Pfister

13A #5555-A phase II trial of biweekly gemcitabine and paclitaxel (GEMTAX) combination in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group study.

Kathleen Elizabeth Bickel

13B #5556-A phase II study of GW786034 (pazopanib) in Asian patients with recurrent/metastatic undifferentiated nasopharyngeal carcinoma.

Wan Teck Lim

13C #5557-Efficacy of combining targeted therapies cetuximab and dasatinib for resistant salivary gland carcinomas in vitro.

Andrew Brohl

13D #5558-Combined hedgehog and epidermal growth factor receptor (EGFR) inhibition in a direct patient tumor model (DPTM) of head and neck squamous cell cancer (HNSCC).

Stephen B Keysar, PhD

13E #5559-Activity of novel RET inhibitors against RET genotypes associated with medullary thyroid cancer.

Ann Gramza

13F #5560-Mature results of a phase I trial of bortezomib, cisplatin, and radiotherapy for advanced or recurrent head and neck cancer.

Rita Susan Axelrod

13G #5561-Phase I trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer.

Johnny Kao

13H #5562-HN5: A phase I/II study of erlotinib as adjuvant therapy in patients treated by chemoradiation therapy (CRT) for locally advanced SCCHN.

Denis Soulieres

14A #5563-The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LAHNC): Preliminary toxicity report.

Robert I. Haddad

14B #5564-Interim safety analysis of a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-) paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in patients with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC).

Brian Andrew Van Tine

14C #5565-Results from a pilot study of nimotuzumab with concurrent chemoradiation in patients with locally advanced squamous cell carcinoma of head and neck.

Madhur Gupta

14D #5566-Hyperfractionated radiation therapy and concurrent chemotherapy for advanced head and neck cancer.

Khaled Ahmed AL Saleh

14E #5567-Concurrent chemoradiation in stage II laryngeal carcinomas.

Rejiv Rajendranath

14F #5568-Network meta-analysis (MA) of taxane-based neoadjuvant chemotherapy (NCT) for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

John Paul McGhie

14G #5569-Induction chemotherapy with carboplatin and paclitaxel followed by radiotherapy and concurrent weekly carboplatin plus paclitaxel in locally advanced nasopharyngeal carcinoma in a nonendemic population.

Gianmauro Numico

14H #5570-Phase II study of synchronous chemoradiotherapy with capecitabine in patients with locally advanced squamous cell carcinoma of the head and neck.

Apurna Jegannathan

15A #5571-Organ preservation using carboplatin, capecitabine, docetaxel, and radiotherapy in head and neck cancer: A phase II study.

Daniel F. Saragiotto

15B #5572-Prediction of outcome of TPF with or without cetuximab induction chemotherapy in head and neck squamous cell carcinoma (HNSCC) using the FLAVINO assay.

Andreas Dietz

15C #5573-The persistence of symptom burden after radiation treatment for head and neck cancer (HNC).

David Ira Rosenthal

15D #5574-Oncologically endoscopic nasopharyngectomy for T1/T2a and selected T2b/T3 nasopharyngeal malignancies with nasopharynx resurfaced with posterior pedicle nasal mucoperiosteum flap.

Ming-Yuan Chen

15E #5575-A comparison between surgery plus radiotherapy and exclusive chemoradiation therapy regimes in oral and oropharyngeal cancer: Long-term functional and psychological impact.

Mario Airoidi

15F #5576-Chemotherapy-enhanced accelerated radiotherapy for intermediate-volume hypopharyngeal cancer.

Mitsuhiko Kawashima

15G #5577-An open, multicenter clinical study on cetuximab combined with intensity modulated radiotherapy (IMRT) plus concurrent chemotherapy in nasopharyngeal carcinoma (NPC): Preliminary report.

Tai-xiang Lu, Prof., Dr.

15H #5578-Competing mortality in advanced head and neck cancer: A population-based study.

Brent Shane Rose

16A #5579-Functional outcomes after cisplatin (C)-based concurrent chemoradiation (CCRT) in patients (pts) with human papillomavirus (HPV)-related squamous cell carcinoma of the oropharynx (SCCOP).

Cristina P. Rodriguez

16B #5580-Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): Preliminary toxicity results.

David N. Hayes

16C #5581-Toxicity and one-year tumor control with induction chemotherapy and bioradiotherapy for locally advanced unresectable head and neck cancer.

Clas Mercke

16D #5582-Long-term treatment outcome of nasopharyngeal carcinoma (NPC) using intensity-modulated radiotherapy (IMRT).

Michael K. Kam

16E #5583-Postoperative adjuvant chemoradiotherapy versus radiotherapy alone for head and neck squamous cell carcinoma: A meta-analysis evaluating the role of chemotherapy schedules.

Gustavo A Viani

16F #5584-Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): First overview of complete data set.

Paul M. Harari

16G #5585-Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): Findings related to the oropharynx.

Stuart J. Wong

16H #5586-Phase I trial of combination sorafenib and tipifarnib: The experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC).

Maria E. Cabanillas

17A #5587-A phase II study of VEGF trap (aflibercept) in patients with radioactive iodine-refractory, positron emission tomography (PET) positive thyroid carcinoma.

Eric Jeffrey Sherman

17B #5588-Epidemiology, treatment outcome, and survival of anaplastic thyroid cancer (ATC) in the United States: A period prevalence SEER database study 1973-2006.

Akm Mosharraf Hossain

17C #5589-Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer.

R. Donald Harvey

17D #5590-Sorafenib in patients (pts) with advanced thyroid carcinoma (TC): A compassionate use program.

Jaume Capdevila

17E #5591-Intensity-modulated radiation therapy combined with concurrent and adjuvant chemotherapy in anaplastic thyroid carcinoma: A single-institution study.

Keith Christopher Bible

17F #5592-Use of cystatin C as a biomarker for glomerular filtration rate in patients with head and neck cancer receiving cisplatin-based chemotherapy.

Edwin Boelke

17G #5593-Effects of aprepitant use in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with high-dose cisplatin and radiation (RT).

Michael Ong, MD, FRCPC

17H #5594-Prognostic significance of epithelitis by concurrent cetuximab and radiotherapy (RT) for locally advanced head and neck squamous cell carcinoma (HNSCC) patients (Pts).

Juan J. Grau

18A #5595-Economic burden of resected squamous cell carcinoma of the head and neck (SCCHN) in a U.S. managed care population.

Benjamin Chastek

18B #5596-Survival from head and neck cancers based on socioeconomic status in Asians.

Karen P. M. Chu

18C #5597-Stress and depression in head and neck cancer patients by primary surgery versus primary radiotherapy treatment modality.

Courtney Ann Jensen

18D #5598-Comparison of quality of lives between voice-rehabilitated and nonrehabilitated laryngectomees in a developing world community.

Bipin Thomas Varghese

18E #5599-Do the treatment outcome priorities of head and neck cancer patients change after undergoing radiation treatment?

Hoda Badr

18F #5600-The relationship of presenting symptom burden and survival in patients with head and neck cancer (HNC).

Gary Brandon Gunn

18G #5601-Routine versus clinically indicated post-treatment surveillance in head and neck cancer.

Neil M. Iyengar, MD

Session Title: #206: Lung Cancer - Local-Regional and Adjuvant Therapy

Session Type: General Poster Session

Date: Sunday, June 6

Location: S Hall A2

Time: 8:00 AM - 12:00 PM

19A #7027-Prognostic impact of the cytoskeleton regulatory protein hMena in resected node-negative non-small cell lung cancer (NSCLC): A clinical-biological risk stratification model.

Emilio Bria

19B #7028-Prognostic value of three microRNA expression profiles in early-stage squamous cell lung cancer (SqCLC).

Marcin Tomasz Skrzypski

19C #7029-VDAC1 and prognosis in surgically resected non-small cell lung cancer.

Claire ME Grills

19D #7030-Cost-effectiveness of an autoantibody test (AABT) as an aid to diagnosis of lung cancer.

Derek Weycker

19E #7031-Use of telomere length in peripheral leukocytes to predict risk of recurrence in patients with early-stage non-small cell lung cancer after curative resection.

Eric S. Kim

19F #7032-Use of serum autoantibodies to identify early-stage lung cancer.

Laura Peek

19G #7033-Demographics of populations at high risk of lung cancer and results of the Early CDT-Lung test.

J. Mathew

19H #7034-Postoperative survivin expression in stage III non-small cell lung cancer (NSCLC) patients treated with neoadjuvant chemoradiation.

Mary J. Fidler

20A #7035-Proposal of new CT response criteria in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor.

Ho Yun Lee

20B #7036-Final results of a phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM).

Anna K. Nowak

20C #7037-CALGB 30601: A phase II study of dasatinib (D) in patients (pts) with previously treated malignant mesothelioma (MM).

Arkadiusz Dudek

20D #7038-A phase II study of sorafenib in malignant mesothelioma with pharmacodynamic imaging using 18fdg-PET.

Sheeba Irshad

20E #7039-A new prognostic score in patients with malignant pleural mesothelioma.

Giovanni Selvaggi

20F #7040-A retrospective analysis of second-line chemotherapy for malignant pleural mesothelioma (MPM).

Nicla Maria La Verde

20G #7041-Vinorelbine (V) in pemetrexed-pretreated patients (PTS) with malignant pleural mesothelioma (MPM).

Elena Lorenzi

20H #7042-Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma.

Anne S. Tsao

21A #7043-A multimodality treatment for malignant pleural mesothelioma patients with or without lymph node metastases.

Keith A Cengel

21B #7044-Phase II trial of consolidation chest radiotherapy for extensive-stage small cell lung cancer.

Don Yee

21C #7045-Pretreatment positron emission tomography (PET) scan standardized uptake value (SUV) as a prognostic variable for overall survival in limited-stage small cell lung cancer (L-SCLC).

Daniel R Gomez

21D #7046-A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC).

Charles M. Rudin, MD, PhD

21E #7047-Should large cell neuroendocrine carcinoma of the lung (LNEC) be classified and treated as a small cell lung cancer (SCLC) or with other large cell carcinomas (OLC)?

Malcolm M. DeCamp

21F #7048-Sabarubicin (SABA) in combination with cisplatin (DDP): Maximum tolerated dose (MTD) evaluation (phase I step) followed by a phase II step in patients (pts) with small cell lung cancer-extensive disease (SCLC-ED).

Oliver A. Cornely

21G #7049-Phase II study of irinotecan, carboplatin followed by maintenance sunitinib in the first-line treatment of extensive-stage small-cell lung cancer.

Eric T. Lubiner

21H #7050-Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC).

John V Heymach, MD, PhD

22A #7051-Long-acting somatostatin analogues survival differences in limited and extensive disease SCLC patients.

Kostas Zarogoulidis

22B #7052-Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).

Mary O'Brien

22C #7053-Retrospective study of irinotecan plus cisplatin induction followed by concurrent thoracic irradiation with irinotecan plus cisplatin chemotherapy for limited-disease small cell lung cancer.

Jaeheon Jeong

22D #7054-A phase II trial of combination chemotherapy with topotecan and amrubicin in small cell lung cancer (SCLC).

Naoyuki Nogami

22E #7055-Phase II study of oral topotecan plus bevacizumab (topo-bev) for second-line treatment of small cell lung cancer (SCLC).

David Michael Waterhouse

22F #7056-Combination chemotherapy with sunitinib (IND 74019; NSC 736511) for untreated extensive-stage small cell lung cancer (SCLC): CALGB 30504 phase IB safety results.

Neal Ready

22G #7057-Phase II study of amrubicin and carboplatin in patients with the refractory or relapsed small cell lung cancer (SCLC).

Takashi Hirose

23A #7059-Five-year follow-up of preoperative chemotherapy (Cx) of docetaxel with or without cisplatin for clinical (c-) stage IB/II non-small cell lung cancer (NSCLC): Report of a Japan Clinical Oncology Group Study (JCOG0204).

Hideo Kunitoh

23B #7060-Evaluation of neoadjuvant "window of opportunity" trials with targeted therapy in patients with surgically resectable non-small cell lung cancer.

Brendon Matthew Stiles

23C #7061-Does induction chemoradiation effect perioperative mortality and overall survival in patients undergoing pneumonectomy for non-small cell lung cancer?

Jacqueline Oxenberg

23D #7062-Multicenter phase II study evaluating docetaxel, CDDP, and cetuximab as induction regimen prior to surgery in chemotherapy-naive patients with NSCLC stage IB-IIIA (INN06-study): Preliminary results.

Wolfgang Hilbe

23E #7063-Docetaxel plus cisplatin versus vinorelbine plus cisplatin as adjuvant chemotherapy in stage IB-IIIA non-small cell lung cancer: Preliminary result of phase II pilot trial CHL001/TAX622.

Da-Tong Chu

23F #7064-Multimodal management of locally advanced (N2) non-small cell lung cancer (NSCLC): Is there a role for surgical resection? A single institution experience.

Joaquim Bosch-Barrera

23G #7065-The impact of PET imaging on outcomes in patients with stage III non-small cell lung cancer (NSCLC) treated with chemoradiation: A subset analysis of HOG LUN 01-24/USO-023.

Nagesh H. Jayaram

23H #7066-Role of surgery in patients with stage IIIA non-small cell lung cancer (NSCLC): Lessons learned from a tertiary referral cancer center experience.

Charu Aggarwal

24A #7067-Influence of surgical interventions on survival in patients with stage IIIb non-small cell lung cancer (NSCLC): The Fox Chase Cancer Center (FCCC) experience.

Walter J Scott

24B #7068-Surgeon-determined variability in quality of surgical resection of lung cancer.

Robert A. Ramirez, DO

24C #7069-Confirmation of the role of diabetes in the local recurrence of surgically resected non-small cell lung cancer.

Abram Recht, MD

24D #7070-Review of mediastinal lymph node examination (mLNE) in a lung cancer resection (LCR) cohort.

Raymond U. Osarogiagbon

24E #7071-Accuracy of endobronchial ultrasound-directed transbronchial needle aspiration (EBUS-TBNA) for mediastinal staging in patients (pts) with non-small cell lung cancer (NSCLC).

Maria Gabriela Tupayachi

24F #7072-Does the revised TNM staging system for lung cancer better estimate actuarial rates of local/regional recurrence after surgery?

Joseph M. Pepek

24G #7073-Solitary pulmonary nodules (SPNs): Outcome of six-year follow-up by a VA multidisciplinary lung cancer group.

Harvey B. Niell

24H #7074-Examination of the influence that lymphatic and venous involvement gives consequence of stage I non small-cell lung cancer in new TNM classification.

Katsuo Kojima

25A #7075-Racial disparities on the use of invasive and noninvasive staging in patients (pts) with non-small cell lung cancer (NSCLC).

Jennifer Marie Suga

25B #7076-Survival of non-small cell lung cancer (NSCLC) patients in a randomized trial as predicted by the FDG-PET standardized uptake value (SUV).

Karen Y. Gulenchyn

25F #7077-Use of PET-measured response in involved mediastinal lymph nodes to predict overall survival (OS) in non-small cell lung cancer (NSCLC) patients treated with induction therapy (IT) and surgery.

Stephen Barnett

25G #7078-A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation.

Joel W. Neal

25H #7079-Health-related quality of life (HRQOL) after stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC).

Suresh Senan

26A #7080-Stereotactic radiosurgery for stage I NSCLC in medically inoperable patients: A prospective multicenter study.

Arjun Pennathur

26B #7081-Photodynamic therapy using NPe6 for bronchogenic carcinomas in central airways more than 1.0 cm in diameter.

Jitsuo Usuda

26F #7082-Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/b non-small cell lung cancer: Interim update.

Hak Choy

26G #7083-Randomized phase II trial of tegafur-uracil (UFT) and cisplatin versus vinorelbine and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-small cell lung cancer: NJLCG 0601.

Makoto Maemondo

26H #7084-Safety and efficacy trial of cisplatin (P) with vinorelbine (V) followed by gefitinib (G) and concurrent thoracic radiotherapy (TRT) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC): Japan Clinical Oncology Group (JCOG) 0402.

Yuichiro Ohe

27A #7085-N0321: A phase I study of bortezomib, paclitaxel, carboplatin (CBDCA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC).

Steven E. Schild, MD

27B #7086-A phase I dose-escalation study using three-dimensional conformal radiotherapy with concurrent cisplatin and S-1 in patients with stage III non-small cell lung cancer.

Takuyo Kozuka

27C #7087-A phase II study of concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage IIIA/b non-small cell lung cancer (NSCLC).

Anthony M. Brade

27D #7088-Vinorelbine and cisplatin concurrently combined with thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer: A long-term safety and efficacy report.

Hidehito Horinouchi

27E #7089-Can we predict two-year survival for radical radiation dosing schedules in advanced non-small cell lung cancer through a meta-analysis based predictive model?

Waseem Sharieff

27F #7090-Docetaxel (D) and cisplatin (C) induction chemotherapy followed by concurrent thoracic radiotherapy (TRT) and biweekly D and C for stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group study.

Joaquin Casal

27G #7091-A Galician Lung Cancer Group phase II study: Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC).

Sergio Vazquez

27H #7092-Concomitant pemetrexed/carboplatin chemotherapy and 3-D conformal radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy for locally advanced non-small cell lung cancer: Preliminary results of a phase II study.

Shenglin Ma

28A #7093-Cisplatin (CDDP) and oral vinorelbine (NVBO) concomitantly with radiotherapy (RT) after induction chemotherapy (CT) in locally advanced (LA) non-small cell lung cancer (NSCLC) treatment: Clinical experience in five institutions in Spain.

Luis Roman

28B #7094-Outcomes of patients with stage III (clinical N2) NSCLC: A VACCR analysis.

Apar Kishor Ganti, MD

28C #7095-Retrospective review of all patients with thymoma treated over the last 33 years at the Royal Marsden Hospital.

Charlotte Benson

28D #7096-Volumetric analysis of advanced thymic malignancies.

Jeremy Force

28E #7097-Clinical features of bronchioloalveolar carcinoma with new histologic and staging definitions.

Ping Yang

28F #7098-Baseline results of lung cancer screening program for family lung cancer risk with low-dose spiral CT in Taiwan.

Chih-Liang Wang

Session Title: #207: Lung Cancer - Metastatic

Session Type: General Poster Session

Date: Sunday, June 6

Location: S Hall A2

Time: 8:00 AM - 12:00 PM

31A #7536-A multicenter phase II randomized study of docetaxel (D)/gemcitabine (G) weekly followed by erlotinib (E) after progression versus erlotinib followed by docetaxel/gemcitabine after progression in advanced non-small cell lung cancer (NSCLC) in fit elderly patients selected with a comprehensive geriatric assessment (CGA): Groupe Français de Pneumocancerologie (GFPC)*0504

Herve Le Caer

31B #7537-Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC).

Tony Mok, MD

31C #7538-EGFR and *ABCG2* polymorphisms as prognostic and predictive markers in the NCIC CTG BR.21 trial of single-agent erlotinib in advanced non-small cell lung cancer (NSCLC).

Geoffrey Liu

32A #7539-Clinical impact of amphiregulin expression in EGFR wild-type non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.

Myung Hee Chang

32B #7540-Biomarker analyses from a phase I study of pertuzumab combined with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).

Enriqueta Felip

32C #7541-Association of *KRAS* and *EGFR* mutations with survival in patients with advanced lung adenocarcinoma.

Melissa Lynne Johnson

33A #7542-EGFR mutation status and survival after diagnosis of brain metastasis in non-small cell lung cancer.

April F. Eichler

33B #7543-Rates of CNS progression in patients with advanced NSCLC harboring somatic EGFR mutations and treated with gefitinib or erlotinib.

Stephanie Heon

33C #7544-Clinicopathologic differences between lung cancer with EGFR gene major (exon 19 deletions and exon 21 L858R) and other minor mutations.

Yuki Yamane

34A #7545-The usefulness of 18f-fluorothymidine (FLT) and 18f-FDG PET for early prediction of response to erlotinib therapy in patients with advanced non-small cell lung cancer.

Chang-Min Choi

34B #7546-Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastasized non-small cell lung cancer (NSCLC): results of the nonrandomized phase II study TaxErb.

Jurgen R. Fischer

34C #7547-A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC).

Byoung Chul Cho

35A #7548-Patient selection for cetuximab in NSCLC: A systematic review of candidate predictive biomarkers.

Christopher Harbison

35B #7549-Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR in-frame deletions of exon 19 according to the size of the deletion.

Miquel Taron

35C #7550-Association of epithelial mesenchymal transition (EMT) markers and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib.

Neel Bhupendra Shah

35D #7551-Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

Jin Seok Ahn

35E #7552-The association between *PTEN* expression and survival in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with erlotinib.

Thomas A. Hensing

35F #7553-Insulin-like growth factor binding proteins related to progression-free survival (PFS) and overall survival (OS) in advanced non-small cell lung cancer (NSCLC) patients treated with chemotherapy.

Reem Karmali

35G #7554-SNaPshot multigene assay to detect mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs).

Belinda A. Waltman

35H #7555-Expression of MET, IGF-1R, IL-6/gp130, and AXL in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.

Carlota Costa

36A #7556-First-cycle rash as a clinical marker in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy (CT) plus cetuximab: Efficacy by histology.

Kenneth John O'Byrne

36B #7557-Phase II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

Gregory J. Riely, MD, PhD

36C #7558-Association of gender and passive smoking with epidermal growth factor receptor mutations in never-smokers with non-small cell lung cancer: A prospective study based on detailed passive smoking questionnaire.

Tomoya Kawaguchi

36D #7559-A phase II study of gefitinib versus vinorelbine or gemcitabine in chemotherapy-naïve elderly patients with advanced non-small cell lung cancer based on epidermal growth factor receptor mutation status.

Shiro Fujita, MD, PhD

36E #7560-Assessment of epidermal growth factor receptor (EGFR) and K-ras mutation status in cytologic stained smears of non-small cell lung cancer (NSCLC) patients.

Maria Dolores Lozano

36F #7561-First-line gefitinib therapy for elder advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: Multicenter phase II trial (NEJ 003 study).

Yuji Minegishi

36G #7562-Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of MET, EGFR, KRAS, and PIK3CA mutations.

Vienna Ludovini

36H #7563-Predictive value of serum HGF for treatment response to EGFR tyrosine kinase inhibitor in patients with lung adenocarcinoma.

Kazuo Kasahara

37A #7564-Effect of tumor-specific KRAS mutational status on impact of anti-EGFR therapy in non-small cell lung cancer (NSCLC).

Marina Chiara Garassino

37B #7565-Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older) with advanced non-small cell lung carcinoma (NSCLC): A randomized phase II study of the German Thoracic Oncology Working Group.

Martin Reck

37C #7566-Comparison of adverse events of erlotinib with those of gefitinib in Japanese patients with NSCLC.

Tomohiro Suzumura, MD

37D #7567-Changes in FDG- and FLT-PET imaging in patients with non-small cell lung cancer (NSCLC) following treatment with erlotinib (E).

Linda Mileshkin

37E #7568-Plans of American medical oncologists (AMO) to order molecular testing before starting first-line therapy for patients with stage IV non-small cell lung cancer (NSCLC).

Mark R. Green

37F #7569-Phase II randomized study of the safety, efficacy, metabolism, and molecular targets of erlotinib in African Americans (AA) with NSCLC.

Miguel Angel Villalona-Calero, MD

37G #7570-Immunohistochemistry (IHC) with EGFR mutation-specific monoclonal antibodies (mAbs) for screening EGFR mutations in non-small cell lung cancer (NSCLC) patients (p).

Sara Simonetti

37H #7571-The efficacy of low-dose gefitinib for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations: A post-hoc analysis from NEJ002.

Akira Inoue

38A #7572-Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.

Wee-Lee Yeo

38B #7573-Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.

Atsushi Horiike

38C #7574-A phase I/IIa study of icotinib hydrochloride, a novel oral EGFR-TKI, to evaluate its safety, tolerance, and preliminary efficacy in advanced NSCLC patients in China.

Qiong Zhao, MD

38D #7575-Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL).

Caicun Zhou

38E #7576-Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC).

Tom Stinchcombe, MD

38F #7577-First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small cell lung cancer patients.

Chien-Hao Lie, MD

38G #7578-Efficacy and safety of bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer (NSCLC).

Davide Tassinari

38H #7579-Comparison of response rate of advanced non-small lung cancer patients to liposomal cisplatin versus cisplatin both combined with paclitaxel: A phase III trial.

George Stathopoulos

39A #7580-Open-label phase II study of S-1 as second-line therapy for patients with advanced non-small cell lung cancer (NSCLC).

Ramaswamy Govindan, MD

39B #7581-Phase II study of sunitinib in patients with non-small cell lung cancer (NSCLC) and irradiated brain metastases: Final efficacy and safety results.

Silvia Novello, MD, PhD

39F #7582-Systemic gene therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer.

Charles Lu

39G #7583-BRIDGE: An open-label phase II trial evaluating the safety of bevacizumab (BV) plus paclitaxel/carboplatin (PC) as first-line treatment (tx) for patients (pts) with advanced, previously untreated, squamous non-small cell lung cancer (NSCLC).

Leonardo Faoro

39H #7584-A randomized phase III study of cisplatin and docetaxel with or without irinotecan in pts with advanced non-small cell lung cancer: Okayama Lung Cancer Study Group OLCSG 0403.

Katsuyuki Kiura

40A #7585-Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC).

Merrill S. Kies, MD

40B #7586-Results of a phase I/II trial of amrubicin (AMR) in combination with cisplatin (CDDP) as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC).

Takashi Seto

40F #7587-Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial.

Edward Garon

40G #7588-A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC).

D. Ross Camidge, MD, PhD

40H #7589-Phase II study of bavituximab plus paclitaxel and carboplatin in untreated locally advanced or metastatic non-small cell lung cancer: Interim results.

Raghunadharao Digumarti

41A #7590-Linifanib treatment in patients with non-small cell lung cancer (NSCLC): Phase II results.

Ross A. Soo, MD

41B #7591-First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or pemetrexed, in Asian, never-smoker (n/smkr) patients (pts) with advanced NSCLC: An open-label, randomized phase II trial.

Jun Liang

41C #7592-Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC).

Alain C. Mita

41D #7593-A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.

David R. Spigel

41E #7594-Phase II study of dasatinib in patients with advanced non-small cell lung cancer.

Faye M. Johnson

41F #7595-Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with measurable asymptomatic inoperable brain metastases (BM): A multicenter phase II trial (GFPC 07-01).

Gilles Robinet

41G #7596-PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E).

Alicyn Campbell

41H #7597-Phase III study comparing vinorelbine/gemcitabine with vinorelbine/carboplatin as first-line chemotherapy of advanced NSCLC: A Norwegian Lung Cancer Study Group trial.

Øystein Fløtten

42A #7598-Results of phase IV clinical trial of combining endostar with chemotherapy for treatment of advanced non-small cell lung cancer (NSCLC).

Jinwan Wang

42B #7599-PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study.

Keunchil Park

42C #7600-A phase I/II trial of pemetrexed and sirolimus in advanced NSCLC.

Gideon Michael Blumenthal

42D #7601-Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small cell lung cancer.

Dianna Shipley

42E #7602-A nonrandomized, multicenter, phase II study of S-1 with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC).

Dennie V. Jones

42F #7603-A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).

Grace K. Dy

42G #7604-Final results of a phase II trial of S-1 with biweekly docetaxel for non-small cell lung cancer previously treated with platinum-based chemotherapy (NJLCG0701).

Osamu Ishimoto

42H #7605-Docetaxel (D) plus gemcitabine (G) compared with G in elderly patients with advanced non-small cell lung cancer (NSCLC): Preliminary results of a randomized phase III Hellenic Oncology Research Group trial.

Athanasios Karampeazis

43A #7606-Prognostic versus predictive value of EML4-ALK translocation in metastatic non-small cell lung cancer.

Alice Tsang Shaw

43B #7607-Use of germline polymorphisms in VEGF to predict tumor response and progression-free survival in non-small cell lung cancer (NSCLC) patients treated with sorafenib: Subset pharmacogenetic analysis of Eastern Cooperative Oncology Group (ECOG) trial E2501.

Wu Zhang

43D #7609-Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial.

Roy S. Herbst

43E #7610-EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients.

Giuseppe Altavilla

43F #7611-Molecular profiling of smoking-related non-small cell lung cancer (NSCLC) phenotypes.

John H. Strickler

43G #7612-In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC).

Rebecca Suk Heist

43H #7613-Eicosanoids in non-small cell lung cancer (NSCLC).

David H. Johnson, MD, FACP

44A #7614-Serum VEGF and COX-2/5LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.

Martin J. Edelman, MD

44B #7615-Correlation of pharmacogenetic markers with docetaxel-based chemotherapy resistance in patients with advanced/metastatic non-small cell lung cancer.

Chara Papadaki

44C #7616-Correlation of genetic polymorphisms in folate metabolic pathway genes with clinical outcomes in pemetrexed-treated advanced NSCLC patients.

Jung A. Kim

44D #7617-Phase II trial of personalized chemotherapy in stage IV NSCLC: Clinical application of functional profiling in first-line therapy.

Robert Alan Nagourney

44E #7618-Clinical outcomes (CO) for special populations of patients (pts) with advanced non-small cell lung cancer (NSCLC): Results from ARIES, a bevacizumab (BV) observational cohort study (OCS).

Antoinette J. Wozniak

44F #7619-Baseline (BL) radiographic characteristics and severe pulmonary hemorrhage (SPH) in bevacizumab (BV)-treated non-small cell lung cancer (NSCLC) patients (pt): Results from ARIES, an observational cohort study (OCS).

Priya Kumar

44G #7620-Expression of sonic hedgehog and its receptor patched in non-small cell lung cancer.

Omid Rouhi

44H #7621-DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma (NSLA).

Ji-Youn Han

45A #7622-Effect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial.

James R. Rigas

45B #7623-Time trend in treatment-related deaths of patients with advanced non-small cell lung cancer enrolled into phase III trials of systemic treatment.

Yoshiro Fujiwara

45C #7624-Progression-free survival (PFS) and overall survival (OS) in phase III trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).

Katsuyuki Hotta

45D #7625-Comparison of efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis.

Gaetan Des Guetz

45E #7626-Evaluation of Kras mutations and angiogenic biomarkers in patients with advanced non-small cell lung cancer (NSCLC) receiving single-agent sorafenib (S).

Ronan Joseph Kelly

45F #7627-Genomic polymorphisms of drug metabolisms associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with gemcitabine (GEM) or taxanes.

Ling Zhang

45G #7628-Randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line chemotherapy in advanced non-small cell lung cancer.

Silke Nagel

45H #7629-Impact of the algorithm for declaring exact progression date on progression-free survival (PFS) estimates in advanced lung cancer clinical trials.

Sumithra J. Mandrekar

46A #7630-Circulating tumor cells (CTC) in small cell lung cancer (SCLC), a promising prognostic factor.

Thijo Jeroen Nicolaas Hiltermann, MD, PhD

46B #7631-ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial.

Michael Schuster

46C #7632-HIV-associated lung cancer in the era of highly active antiretroviral therapy (HAART): Correlation between CD4 count and outcome.

Suchita Pakkala

46D #7633-Survival impact of newly approved therapeutic agents in patients with advanced non-small cell lung cancer (NSCLC): A SEER-Medicare database analysis.

Taofeek Kunle Owonikoko, MD

46E #7634-First-line systemic therapy in metastatic non-small cell lung cancer (mNSCLC) patients treated at National Comprehensive Cancer Network (NCCN) institutions: An analysis from the NCCN Oncology Outcomes Database Project.

Jonathan L. Vandergrift

46F #7635-Brain metastases (mets) in lung cancer patients (pts): Analysis of the Detroit Surveillance, Epidemiology and End Results (SEER) data.

Shirish M. Gadgeel, MD

46G #7636-Prognostic impact of malignant pleural effusion in patients with stage M1b non-small cell lung cancer.

Daniel Morgensztern

46H #7637-Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials.

Nathan R Foster

47A #7638-Ethnic difference in toxicity in non-small cell lung cancer patients treated with chemotherapy: A systematic review on phase II and III clinical trials.

Yoshikazu Hasegawa

47B #7639-Improving the accuracy of FNA lung biopsies in a community hospital.

Ashantice Higgins, MD

Session Title: #209: Melanoma/Skin Cancers

Session Type: General Poster Session

Date: Sunday, June 6

Location: S Hall A2

Time: 8:00 AM - 12:00 PM

48A #8533-Phase I/II study of the combination of decitabine (DAC) and temozolomide (TMZ) in patients (pts) with metastatic melanoma (MM).

Hussein Abdul-Hassan Tawbi

48B #8534-Chemoablation of metastatic melanoma with rose bengal (PV-10).

Sanjiv S. Agarwala

48C #8535-A phase I trial of intra-lymph-node administration of a novel immunotherapeutic regimen (MKC1106-MT) in patients with advanced melanoma.

Jeffrey S. Weber

48D #8536-Dacarbazine (DTIC) plus bevacizumab (B) combination therapy in chemotherapy (CTH)-naïve advanced melanoma (MM) patients (pts): A phase II study.

Alessandra di Pietro

48E #8537-Plitidepsin (APL) alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM).

Elizabeth R. Plummer

48F #8538-Evaluation of FOXP3 microsatellite polymorphisms in high-risk melanoma patients receiving adjuvant interferon.

Helen Gogas

48G #8539-Screening tools for interferon-related cognitive decline in melanoma patients.

Daniel Combs

48H #8540-The impact of multiple primary cutaneous melanomas on survival of 2,942 patients with metastatic melanoma.

Rajmohan Murali

49A #8541-A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma.

John Munn Kirkwood

49B #8542-Prognostic factors for survival after first recurrence of melanoma.

Ting Tu

49C #8543-Correlation of polymorphic variants into the susceptibility of CDKN2 locus with melanoma outcome.

Giuseppe Palmieri

49D #8544-Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: Long-term follow-up of 179 patients with metastatic melanoma.

Peter A Prieto, MD, MPH

49E #8545-Sunitinib therapy for metastatic melanomas with KIT aberrations.

David R. Minor

49F #8546-Preclinical analyses of a new gamma-secretase inhibitor targeting notch signaling in melanoma.

Laura Poliseno

49G #8547-Clinical outcome following therapeutic vaccination with autologous mRNA electroporated dendritic cell (DC) vaccines in patients with advanced melanoma.

Sofie Wilgenhof

49H #8548-Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma.

Georgina Long, MBBS, PhD, FRACP

50A #8549-A predictive model to determine the likelihood of positive sentinel lymph node biopsy in thin melanomas.

Suraj S. Venna

50B #8550-Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM): 1-year OS update.

Vojislav M. Vukovic

50C #8551-Correlation of stem cell marker nestin expression on circulating melanoma cells with extension of disease and survival.

Alberto Fusi, MD

50D #8552-Phase I/II trial of association of sorafenib in combination with temozolomide in patients with metastatic melanoma: Looking for predictive markers of efficacy.

Caroline Robert

50E #8553-The use of integrative genomics to define molecular signatures of melanoma histologic subtypes.

Amy Elizabeth Rose

50F #8554-Preclinical analysis of targeting miR-182 against melanoma liver metastasis.

Chanh Trung Huynh

50G #8555-Tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in chemotherapy-naïve stage IV melanoma patients.

Benjamin Weide

50H #8556-Patterns of recurrence in 208 patients with Merkel cell carcinoma.

Tawnya Lynn Bowles

51A #8557-Relation between baseline LDH and tumor burden in advanced melanoma in two phase III trials of oblimersen-dacarbazine (OBL-DTIC) versus DTIC.

Celeste Lebbé

51B #8558-MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab (SAKK 50/07).

Adrian F. Ochsenbein

51C #8559-Induction of apoptosis in human melanoma by the BRAF inhibitor PLX4720: The key to therapeutic success?

Peter Hersey

51D #8560-Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanoma.

Jose Lutzky, MD, FACP

51E #8561-Oblimersen 1-hour IV infusion in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma.

Patrick Alexander Ott

51F #8562-Phase II study of the src family kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.

Thomas Gajewski, MD, PhD

51G #8563-The impact of physician specialty on quality of melanoma care.

Janice N. Cormier

51H #8564-Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab to treat refractory stage IV acral melanoma.

Lu Si

52A #8565-CD20-immunotargeting of malignant melanoma.

Stephan N. Wagner

52B #8566-Enhancing DNA repair in the skin: A pilot study of low-dose chloroquine and ultraviolet light.

Holly E Kanavy

52C #8567-Changes in regional immunity and metastasis in melanoma.

Aaron Scott Mansfield

52D #8568-Effect of TLR4 engagement on TLR3-induced proinflammatory signaling in dendritic cells through IL-10, STAT3, and p38-dependent pathways and on antimelanoma CD8+ T-cell priming.

Dusan Bogunovic

52E #8569-Interleukin-2-induced fever in relation to objective tumor response and survival in patients with metastatic melanoma.

Mai-Britt Bjørklund Ellegaard, MA

52F #8570-Identification of tyrosinase polymorphisms for use in melanoma risk assessment.

Eleftheria Pervolaraki

52G #8571-Hair depigmentation as an indicator of durable response to CTLA-4 therapy.

Anna C. Pavlick, MD

52H #8572-N0675: NCCTG phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma (MM).

Roxana Stefania Dronca

53A #8573-Results of pooled analyses from two phase III trials of 1,085 patients (pts) with advanced melanoma: Oblimersen (OBL) plus dacarbazine (DTIC) versus DTIC alone.

Agop Y. Bedikian

53B #8574-Effect of a novel cross-talk mechanism on the RAF/MEK/ERK and PI3K/AKT/mTOR pathways in melanoma: Role of ERK-mediated suppression of PTEN expression.

Ludovica Ciuffreda

53F #8575-In vivo metabolic activity and transcriptional profiling in melanoma (MM) patients during sorafenib and dacarbazine (DTIC) treatment.

Marjam Jeanette Barysch

53G #8576-Role of lymph-node ultrasonography (US) in the follow-up of melanoma patients to detect nodal recurrence after sentinel lymph node biopsy (SNLB): A prospective cohort study.

Philippe Saiag

53H #8577-Final results of a pilot study using sunitinib malate in patients with stage IV uveal melanoma.

Lukman Adeoju Tijani

54A #8578-Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trial of unresectable stage IV melanoma treated with *nab*-paclitaxel and carboplatin: A translational study of NCCTG trial N057E.

Svetomir Markovic

54B #8579-Management of cutaneous metastases by electrochemotherapy.

Julie Gehl

54F #8580-Immunomodulatory gene expression at the fetomaternal interface and in melanoma: Tolerance meets inflammation.

Shernan G. Holtan

54G #8581-Diagnostic imaging modalities for the surveillance of melanoma patients: A meta-analysis.

Yan Xing

54H #8582-Relationship between dose, exposure, and antitumoral activity of sorafenib in melanoma.

Nicolas Pécuchet

55A #8583-Patterns of disease spread in metastatic mucosal melanoma.

Kevin N O'Regan

55B #8584-Targeting SRC kinase (SRC) in melanoma cells.

Alex J. Eustace

55C #8585-Predictive and prognostic potential of angiogenic serum factors and circulating endothelial cells in metastatic melanoma patients receiving temozolamide plus bevacizumab (SAKK 50/07).

Gregor Fuerstenberger

55D #8586-A phase II clinical trial of a novel combinatorial antitumor immunotherapy for patients with high-risk resected stage III and metastatic melanoma.

Adam Irwin Riker

55E #8587-Prognostic value of serum YKL-40 in stage IΙB-III melanoma patients receiving adjuvant interferon therapy.

Merete Krogh

55F #8588-Interleukin-10 as a prognostic factor in patients treated with autologous melanoma cell vaccine.

Amit Mahipal

55G #8589-Electrochemotherapy with bleomycin: A local treatment with possible systemic implication.

Alessandro Testori

55H #8590-Dual mechanistic function of MDSC subsets in melanoma resistance.

Ernest C. Borden, MD

56A #8591-Immunohistochemical expression of Dicer in melanoma.

Carlo Capalbo

56B #8592-PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial.

Mario E. Lacouture, MD

56D #8594-Utility of 3-year torso CT and head imaging in asymptomatic patients with high-risk melanoma.

Erin Rachelle DeRose

56E #8595-Comparison of classification systems in melanoma sentinel nodes: An analysis of 697 patients from a single center.

Ralf Gutzmer

56F #8596-Prognostic relevance of increased detection of lymphovascular invasion in primary melanoma using D2-40 and CD34 compared to routine histology.

Farbod Darvishian

56G #8597-Effect of mutational status on response, PFS, or OS after treatment with IL-2 for metastatic melanoma.

Richard Wayne Joseph

Session Title: #218: The MEK Pathway

Session Type: Clinical Science Symposium

Date: Sunday, June 6

Location: E354a

Time: 8:00 AM - 9:30 AM

- The MEK Pathway

Alex A. Adjei, MD, PhD

- Discussion: Introduction

David B. Solit, MD

- #2503-Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212.

Jeffrey R. Infante

- #2504-First-in-human phase I; safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors.

Jean-Pierre Delord

- #2505-Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors.

Mitesh J. Borad

- Discussion: Closing

Patricia LoRusso, DO

Session Title: #146: Cancer Prevention/Epidemiology

Session Type: Oral Abstract Session

Date: Sunday, June 6

Location: S100b

Time: 9:30 AM - 12:30 PM

- Cancer Prevention/Epidemiology
Frank Sinicrope, MD
- Cancer Prevention/Epidemiology
Eva Szabo, MD
- #1500-Lynch syndrome *TACSTD1* family with predominant colorectal cancer.
Henry T. Lynch, MD
- #1501-Association of Lynch syndrome and risk of invasive cervical cancer.
Yoland Catherine Antill
- Discussion
Stephen B. Gruber, MD, PhD
- #1502-Long-term survival among 298 Hodgkin lymphoma (HL) patients who develop breast cancer (BC): A population-based study.
Michael T Milano
- #1503-Diabetes, obesity, and survival in a large cohort of early-stage breast cancer patients.
Sharon Hermes Giordano, MD
- #1504-Genetic variants in the telomere maintenance pathway as predictors of second primary tumors and recurrence of early-stage head and neck cancer.
Joshua Y Chang
- #1505-A short-term biomarker modulation prevention study of simvastatin in women at increased risk for breast cancer.
Michaela Jane Higgins, MBChB, MRCP
- #1506-Characterizing benign breast disease in women at high risk for breast cancer.
Sarah A Israel
- #1507-Breast cancer outcome and estrogen plus progestin use in postmenopausal women.
Rowan T. Chlebowski
- Discussion
Powel H Brown, MD, PhD

Session Title: #150: Gastrointestinal (Colorectal) Cancer

Session Type: Oral Abstract Session

Date: Sunday, June 6

Location: E Hall D1

Time: 9:30 AM - 12:30 PM

- Gastrointestinal (Colorectal) Cancer

Chris R. Garrett, MD

- Gastrointestinal (Colorectal) Cancer

Tanios S. Bekaii-Saab, MD

- #3501-Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): The MACRO Trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD]).

Josep Tabernero, MD

- #3502-Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial.

Timothy Stanley Maughan

- #3526-Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM).

Theo Ruers

- Discussion

Alan Paul Venook, MD

- #3503-Comparison of molecular and pathologic features of stage II and stage III colon cancer in 4 large studies conducted for development of the 12-gene colon cancer recurrence score.

Michael J. O'Connell

- #3504-Molecular and clinical determinants of survival following relapse after curative treatment of stage II-III colon cancer (CC): Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial.

Arnaud Roth

- #3505-Mutant KRAS and BRAF gene expression profiles in colorectal cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial.

Sabine Tauber, MD, PhD

- #3506-Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to *KRAS* and *BRAF* mutation status.

Carsten Bokemeyer

- Discussion

Charles Fuchs, MD

- #CRA3507-Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in *KRAS* wild-type (WT) patients (pts) with resected stage III colon cancer (CC): Results from NCCTG Intergroup Phase III Trial N0147.

Steven R. Alberts

- #3508-Adjuvant mFOLFOX6 plus or minus cetuximab (Cmab) in patients (pts) with *KRAS* mutant (m) resected stage III colon cancer (CC): NCCTG Intergroup phase III trial N0147.

Richard M. Goldberg, MD

- Discussion

Louis M. Weiner, MD

Session Title: #152: Genitourinary Cancer (Prostate)

Session Type: Oral Abstract Session

Date: Sunday, June 6

Location: E Hall D2

Time: 9:30 AM - 12:30 PM

- Genitourinary Cancer (Prostate)

Dana E. Rathkopf, MD

- Genitourinary Cancer (Prostate)

Evan Y. Yu, MD

- #CRA4504-Intergroup randomized phase III study of androgen deprivation therapy (ADT) + radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633).

Padraig Richard Warde

- #4505-Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer.

Nicolas Mottet

- #4506-Surgical outcomes and implications for cure in active surveillance patients who undergo delayed radical prostatectomy.

Bruce J Trock, PhD, MPH

- Discussion: Early prostate cancer: How much therapy is too much?

Anthony V D'Amico, MD, PhD

- #LBA4507-A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer

Karim Fizazi

- Discussion: The role of RANKL inhibition in preventing skeletal morbidity from castration resistant prostate cancer

Robert E. Coleman, MD, MBBS

- #4508-Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC).

Johann Sebastian De Bono, MD, PhD

- #4509-Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial.

Howard I. Scher

- Discussion: Chemotherapy for castration resistant prostate cancer: Looking beyond docetaxel and mitoxantrone

Ian Tannock, MD, PhD

- #4510-A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naïve patients with metastatic castrate-resistant prostate cancer (CRPC).

Roberto Pili

- #LBA4511-A randomized, double-blind, placebo controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castrate-resistant prostate cancer (mCRPC): Survival results of CALGB 90401.

William Kevin Kelly

- Discussion: Angiogenic targeting in castration resistant prostate cancer

William L. Dahut, MD

Session Title: #154: Gynecologic Cancer

Session Type: Oral Abstract Session

Date: Sunday, June 6

Location: E Arie Crown Theater

Time: 9:30 AM - 12:30 PM

- Gynecologic Cancer

Amit M. Oza, BSc, MBBS, MD, FRCPC, FRCP

- Gynecologic Cancer

Ernst Lengyel, MD, PhD

- #5003-A prospective U.S. ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA).

Karen H. Lu

- #5004-A gene expression profile of BRCAness that correlates with responsiveness to platinum and PARP inhibitors.

Panagiotis Konstantinopoulos

- #5005-Randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): A NOGGO-AGO-Intergroup study.

Jalid Sehouli, Prof., Dr.

- #5006-RTOG 0417: A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.

Tracey E Schefter

- Discussion: The next Step in Chemo-radiation for cervical cancer.

Patricia J. Eifel, MD

- 5 #5013-Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.

Ignace B. Vergote

- Discussion: Chemotherapy of the future in platinum resistant disease.

Claire F. Verschraegen, MD

- #LBA5008-Phase III trial of induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C) followed by elective T consolidation in advanced ovarian cancer (OC): Final safety and efficacy report.

Michael G. Teneriello

- Discussion: Maintenance and Consolidation in Ovarian Cancer.

Ronald J. Buckanovich, MD

Session Title: #161: Myeloma

Session Type: Oral Abstract Session

Date: Sunday, June 6

Location: E354b

Time: 9:30 AM - 12:30 PM

- Myeloma

Todd M. Zimmerman, MD

- Myeloma

Andrzej J. Jakubowiak, MD, PhD

- #8013-Bortezomib, melphalan, prednisone, and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients.

Mario Boccardo

- #8014-Comparison of reduced-dose bortezomib plus thalidomide and dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.

Philippe Moreau

- Discussion: Sorting through the options for initial therapy of myeloma

Ruben Niesvizky, MD

- #8015- A phase III trial of melphalan/prednisone/lenalidomide (MPR) versus melphalan (200 mg/m²) and autologous transplantation (MEL200) in newly diagnosed myeloma patients.

Antonio Palumbo, MD

- #8016-Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.

Kenneth Carl Anderson

- Discussion: What is the role of transplant for myeloma in the era of novel agents?

Jean L. Harousseau, MD

- #8017-Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.

Philip L. McCarthy, Bsc, MD

- #8018-Lenalidomide maintenance after transplantation for myeloma.

Michel Attal

- #8019-Defining the prognostic variables in gene expression profiling (GEP)-defined high-risk multiple myeloma (MM): Distinguishing early failures (EF) from sustained control (SC).

Bart Barlogie

- #8020-Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.

Sagar Lonial, MD

- #8021-Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX Study.

Gareth Morgan, PhD, FRCP

Session Title: #164: Pediatric Oncology I

Session Type: Oral Abstract Session

Date: Sunday, June 6

Location: S504

Time: 9:30 AM - 12:30 PM

- Pediatric Oncology I

Steven G. DuBois, MD

- Pediatric Oncology I

Kenan Onel, MD, PhD

- #9503-Early results from Children's Oncology Group (COG) ARST0431: Intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS).

Brenda Weigel

- #9504-Second-look operation with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma (RMS): A report from the Children's Oncology Group (COG).

David Anthony Rodeberg

- #9505-Prognostic factors of localized extremity rhabdomyosarcomas: The results of a pooled analysis from U.S. and European cooperative groups.

Odile Oberlin

- #9506-Nonmetastatic osteosarcoma of the extremity: Neoadjuvant chemotherapy with methotrexate (MTX), cisplatin (CDP), doxorubicin (ADM) with or without ifosfamide (IFO)-A randomized trial of the Italian Sarcoma Group (ISG/OS-1).

Stefano Ferrari

- Discussion: Pediatric sarcomas: where to now?

Holcombe E. Grier, MD

- #CRA9507-A phase II trial of proton radiotherapy for medulloblastoma: Preliminary results.

Torunn I. Yock

- #9508-Neurocognitive outcomes after proton radiation for pediatric brain tumors.

Margaret B. Pulsifer

- #9509-Cytogenetic and early-response characteristics of adolescents and young adults with acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study.

Elizabeth A. Raetz

- #9510-Dose-intensified daunorubicin induction and consolidation plus combined modality maintenance therapy for children with newly diagnosed acute promyelocytic leukemia (APL): North American Intergroup study C9710.

James Henry Feusner

- #9511-Advanced-stage anaplastic large-cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial with standard APO (doxorubicin, prednisone, vincristine) versus consolidation with a regimen including vinblastine: A report from the Children's Oncology Group.

Jacqueline M. Kraveka

- Discussion: Bridging the gap in leukemia

James B. Nachman, MD

Session Title: #8: Adjuvant Treatment in Patients over Age 75: When to Treat and When Not to Treat

Session Type: Education Session

Date: Sunday, June 6

Location: S100a

Time: 9:45 AM - 11:00 AM

- Benefits of Adjuvant Therapy

Peter Ravdin, MD

- Estimating life expectancy and benefit from adjuvant therapy based on comorbidity

Supriya Gupta Mohile, MD, MS

- The Importance of Shared Decision-Making Regarding Adjuvant Therapy

Arash Naeim, MD

Session Title: #34: Creative Approaches to Advanced and Metastatic Sarcoma

Session Type: Education Session

Date: Sunday, June 6

Location: S406 (Vista Room)

Time: 9:45 AM - 11:00 AM

- Management of sarcoma patient with lung metastasis - minimally invasive/non resection approaches

Raja Michael Flores, MD

- Role of radiation for treatment of advanced/metastatic sarcoma

Brian O'Sullivan, MD

- Novel systemic approaches for the management of advanced/metastatic sarcoma

William D. Tap, MD

Session Title: #104: Therapy for Patients with Activating Mutations of the Epidermal Growth Factor Receptor

Session Type: Education Session

Date: Sunday, June 6

Location: N Hall B1

Time: 9:45 AM - 11:00 AM

- Mechanisms of resistance to EGFR inhibitors

William Pao, MD, PhD

- Testing for EGFR in Untreated Patients: Implications for Treatment

Tony Mok, MD

- Therapy after progression in first line for patients with activating mutation of the EGFR

David Michael Jackman, MD

Session Title: #119: Nontransplant Options for Mantle Cell Lymphoma

Session Type: Meet the Professor Session

Date: Sunday, June 6

Location: E451b

Time: 9:45 AM - 11:00 AM

- Nontransplant Options for Mantle Cell Lymphoma

John Leonard, MD

Session Title: #140: Therapeutic Choices for Patients with Intermediate-stage Head and Neck Cancer

Session Type: Clinical Problems in Oncology Session

Date: Sunday, June 6

Location: E451a

Time: 9:45 AM - 11:00 AM

- Management Strategies for Intermediate Stage Larynx Cancer

Merrill S. Kies, MD

- Multidisciplinary Treatment of Intermediate Stage Oral Cavity Cancer

Ted Teknos, MD

- Intermediate Stage Oropharyngeal Cancer

Christopher Nutting, MD

Session Title: #217: Smoothened/Hedgehog/Gamma Secretase

Session Type: Clinical Science Symposium

Date: Sunday, June 6

Location: E353

Time: 9:45 AM - 11:15 AM

- Smoothened/Hedgehog/Gamma Secretase

S. Gail Eckhardt, MD

- Discussion: Introduction

Patricia LoRusso, DO

- #2500-A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors.

Jordi Rodon Ahnert

- #2502-A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors.

Anthony W Tolcher

- Discussion: Closing Remarks

Charles M. Rudin, MD, PhD

Session Title: #229: Pharmacologic Treatment of Cancer Related Fatigue: Does it Make a Difference?

Session Type: Clinical Science Symposium

Date: Sunday, June 6

Location: E354a

Time: 9:45 AM - 11:15 AM

- Pharmacologic Treatment of Cancer Related Fatigue: Does it Make a Difference?

Thomas J. Smith, MD

- Pharmacologic Treatment of Cancer Related Fatigue: Does it Make a Difference?

Barbara A. Murphy, MD

- #9004-Long-acting methylphenidate for cancer-related fatigue: NCCTG trial N05C7.

Debra L. Barton

- #9005-Factors associated with response to methylphenidate in advanced cancer patients with cancer-related fatigue.

Sriram Yennurajalingam

- #9006-A randomized double-blind placebo-controlled study of oral coenzyme Q10 to relieve self-reported cancer-treatment-related fatigue in newly diagnosed breast cancer patients.

Glenn Jay Lesser

- #9007-Effect of guarana (*Paullinia cupana*) on fatigue in breast cancer patients undergoing systemic chemotherapy.

Auro del Giglio, MD

- Discussion

Thomas J. Smith, MD

Session Title: #265: Training Program Directors' Special Session - Addressing the Competencies: Professionalism and Practice-Based Learning

Session Type: Special Session

Date: Sunday, June 6

Location: S404

Time: 10:30 AM - 12:30 PM

- QOPI for Fellows Overview

Michael P. Kosty, MD

- Program Directors' Experiences with QOPI for Fellows

Jill Gilbert, MD

- Program Directors' Experiences with QOPI for Fellows

Laurie Jean Lyckholm, MD

- Professionalism

Timothy Jerome Moynihan, MD

Session Title: #44: Evaluating the Evidence and Marketing of Pharmacogenomic Tests

Session Type: Education Session

Date: Sunday, June 6

Location: E353

Time: 11:30 AM - 12:45 PM

- Overview of pharmacogenomics: history, development and role in FDA labeling

Howard L. McLeod, PharmD

- Cyp2D6 testing and tamoxifen

Matthew P. Goetz, MD

- Clinical cases in pharmacogenomics

Michael L. Maitland, MD, PhD

Session Title: #65: Lessons Learned from Clinical Trials in Gastrointestinal Stromal Tumor

Session Type: Education Session

Date: Sunday, June 6

Location: S406 (Vista Room)

Time: 11:30 AM - 12:45 PM

- Combination therapy with established and novel targeted agents to improve outcomes in patients with advanced GIST

Jean-Yves Blay, MD, PhD

- Dosing the unusual patient with non exon 9/11 GIST

Michael C. Heinrich, MD

Session Title: #96: Survivorship in Lymphoma

Session Type: Education Session

Date: Sunday, June 6

Location: E354a

Time: 11:30 AM - 12:45 PM

- Imaging in Lymphoma Patients: Who, when, how and how long?

Rebecca L. Elstrom, MD

- Long Term Toxicities of Lymphoma Therapy

David J. Straus, MD

- Psychosocial Issues of Lymphoma Survivors: Cured but not healed?

Jennifer Mills, MSW, MPH

Session Title: #117: Electronic/Digital Resources in Oncology: Value versus Distraction

Session Type: Meet the Professor Session

Date: Sunday, June 6

Location: E451b

Time: 11:30 AM - 12:45 PM

- Electronic and Digital Resources in Oncology, Value vs. Distraction

Robert Stephen Miller, MD

Session Title: #132: Lifestyle and Pharmacologic Therapeutics in Colorectal Cancer Survivors: What to Do after Adjuvant Therapy?

Session Type: Clinical Problems in Oncology Session

Date: Sunday, June 6

Location: E451a

Time: 11:30 AM - 12:45 PM

- Pharmacologic interventions to lower the risk of tumor recurrence in patients with resected colorectal cancer

David P. Ryan, MD

- Beyond standard surgery and chemotherapy to lower the risk of tumor recurrence in patients with resected colorectal cancer

Jeffrey A. Meyerhardt, MD, MPH

Session Title: #220: Optimizing Care of the Elderly and Underserved

Session Type: Clinical Science Symposium

Date: Sunday, June 6

Location: S100a

Time: 11:30 AM - 1:00 PM

- Optimizing Care of the Elderly and Underserved

Jennifer A. Ligibel, MD

- Optimizing Care of the Elderly and Underserved

Gretchen Genevieve Kimmick, MD

- #9000-The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score: Design and validation.

Martine Extermann, MD

- #9001-Predicting chemotherapy toxicity in older adults with cancer: A prospective 500-patient multicenter study.

Arti Hurria, MD

- Discussion

Hyman Bernard Muss, MD

- #9002-Racial differences in receipt of guideline-recommended treatment in men with low-, intermediate-, and high-risk prostate cancer (CaP): A population-based study.

Ronald C. Chen

- #9003-Factors contributing to high symptom burden during chemotherapy for advanced lung cancer: The risk of being underserved.

Charles S. Cleeland

- Discussion

Cathy Bradley, PhD

Session Title: #143: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sunday, June 6

Location: N Hall B1

Time: 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture
Daniel F. Hayes, MD
- Plenary Session including Science of Oncology Award and Lecture
Douglas W. Blayney, MD
- Plenary Session including Science of Oncology Award and Lecture
Frank McCormick, PhD, FRS
- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Robert A Burger
- Discussion
Elizabeth A. Eisenhauer, MD
- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).
Elisabeth A. Quoix
- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).
Yung-Jue Bang
- Discussion
Martin J. Edelman, MD
- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O'Day, MD
- Discussion: Ipilimumab: The light at the end of the tunnel?
Vernon K Sondak, MD

Session Title: #176: Developmental Therapeutics - Experimental Therapeutics

Session Type: Poster Discussion Session

Date: Sunday, June 6

Location: E450b

Time: 2:00 PM - 6:00 PM

- Developmental Therapeutics - Experimental Therapeutics

Ross A. Soo, MD

- Developmental Therapeutics - Experimental Therapeutics

Patrick Schoffski, MD, MPH

1 #3015-A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

Roger B Cohen

2 #3016-Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.

Valentine M Macaulay

3 #3017-A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).

Heather A. Wakelee, MD

4 #3018-Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors.

Igor Puzanov

- Discussion: Interrupting Growth Factor Pathways Cross-Talk: Combinations With Erlotinib

Tomislav Dragovich, MD, PhD

5 #3019-Association of the *hemochromatosis (HFE)* gene with pazopanib-induced transaminase elevations in renal cell carcinoma.

Chun-Fang Xu

6 #3020-Effect of coadministration of statins on neutropenia in a phase I genotype-directed dose-escalation study of irinotecan.

Federico Innocenti

7 #3021-Inherited genetic variation in *EPHA5*, *FGD4*, and *NRDG1* and paclitaxel (P)-induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101.

Deanna L. Kroetz

8 #3022 Systemic delivery of siRNA via targeted nanoparticles in patients

9 #3023-Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.

Patricia Tresca

10 #3024-A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors.

Alex A. Adjei, MD, PhD

11 #3025-Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.

Robert C. Newton

12 #3026-Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs).

Emiliano Calvo

13 #3027-A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.

Giuseppe Giaccone

- Discussion: Design of early development combination trials

Elizabeth A. Eisenhauer, MD

14 #3028-Final report of phase I clinical, pharmacokinetic (PK), pharmacodynamic (PD) study of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with solid tumors.

Neesha C. Dhani

15 #3029-Utilizing mechanistic PK/PD modeling to simultaneously examine free CCL2, total CCL2, and CNTO 888 serum concentration time data.

Gerald J. Fetterly

16 #3030-A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.

Irene Brana

17 #3031-Pharmacokinetic (PK) and pharmacodynamic (PD) results from two phase I studies of the investigational selective Aurora A kinase (AAK) inhibitor MLN8237: Exposure-dependent AAK inhibition in human tumors.

Andres Cervantes-Ruiperez

18 #3032-Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110 δ isoform, in patients with relapsed or refractory hematologic malignancies.

Richard R. Furman

19 #3033-Pharmacodynamically guided dose selection of PF-00337210, a VEGFR2 tyrosine kinase (TK) inhibitor, in a phase I study.

Glenn Liu

- Discussion: Applying PK/PD principles to development of anticancer agents.

Jan H. M. Schellens, MD, PhD

Session Title: #181: Gynecologic Cancer

Session Type: Poster Discussion Session

Date: Sunday, June 6

Location: E450a

Time: 2:00 PM - 6:00 PM

- Gynecologic Cancer

Seiko Diane Yamada, MD

- Gynecologic Cancer

Claire F. Verschraegen, MD

1 #5009-A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.

Todd D. Tillmanns

2 #5010-A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study.

Robert L. Coleman, MD

3 #5011-A phase II, nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer.

Benedict B. Benigno

4 #5012-Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study.

Andres Poveda

5 #LBA5012b-PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.

R. Wendel Naumann

6 #5014-Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC).

Elisa Gallerani

7 #5015-Immunotherapy with intraperitoneal catumaxomab in patients with advanced ovarian cancer after a complete response to chemotherapy: A phase II study.

Robert W. Holloway

- Discussion: old wines in new bottles.

Carol Aghajanian, MD

8 #5016-A KRAS-variant as a biomarker of ovarian cancer risk.

Joanne B. Weidhaas

9 #5017-Clinical characteristics and outcomes of BRCA-associated ovarian cancer (OC): Genotype and survival.

Verena Engelstaedter

10 #5018-Breast cancer protein expression as a prognostic marker in sporadic epithelial ovarian cancer (EOC): An NCIC CTG OV.16 correlative study.

Johanne Ingrid Weberpals

11 #5019-Impact of BRCA1 gene alterations on tumor characteristics and clinical outcome in ovarian cancer (OC) patients.

Desislava Dimitrova

12 #5020-Use of microarray-based comparative genomic hybridization analysis to identify prognostic subgroups of ovarian clear cell carcinomas.

David Shao Peng Tan

13 #5021-A gene expression algorithm for the prediction of platinum sensitivity in ovarian cancer.

James Stuart Ferriss, MD

14 #5022-Use of HE4 expression in plasma to predict operative outcome in patients with ovarian cancer (OC).

Elena Ioana Braicu

- Discussion: Biomarkers in ovarian cancer - forward progress or back to the future?

Michael J. Birrer, MD, PhD

16 #5024-Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases.

Rowena Cabigon Mercado

17 #5025-Impact of microsatellite instability in overall survival of women with endometrial cancer.

Jose Claudio Casali da Rocha, MD, PhD

18 #5026-Evaluation of insulin resistance among endometrial cancer patients.

Jennifer K. Burzawa

19 #5027-Influence of radiation modality and nodal dissection on survival in high-risk early-stage endometrial cancer.

Junzo P. Chino

20 #5028-Adjuvant chemotherapy and chemoradiation following surgery for high-risk endometrial cancer.

Kailash Narayan

21 #5029-A phase II trial of radiotherapy sandwiched between carboplatin and docetaxel for stage III, IV, and recurrent endometrial cancer.

Melissa Ann Geller, MD

- Discussion: Whats new in Endometrial Cancer?

Angeles Alvarez Secord, MD

22 #5030-Treatment outcomes for older women with advanced ovarian cancer: Results from a phase III clinical trial (GOG182).

William P. Tew

23 #5031-Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial.

Jean-Emmanuel Kurtz

24 #5032-Defining clinical and statistical improvement in consolidation single-arm trials in ovarian cancer.

David R. Spriggs, MD

25 #LBA5033-Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO-2 randomized multicenter trial.

Sandro Pignata

- Discussion: Mining Phase III studies - gold or quicksilver?

Mahesh Parmar, PhD

Session Title: #190: Pediatric Oncology

Session Type: Poster Discussion Session

Date: Sunday, June 6

Location: S Hall A2

Time: 2:00 PM - 6:00 PM

- Pediatric Oncology

Maryam Fouladi, MD

- Pediatric Oncology

Rochelle Bagatell, MD

39A #9521-High throughput transcriptome sequencing of pediatric relapsed acute lymphoblastic leukemia (ALL).

Laura E. Hogan

39B #9522-Association of a genetic variant in the *ABCC2* gene with high methotrexate plasma concentrations in pediatric malignancies.

Melanie M. Hagleitner

39F #9523-Biomarkers in the prediction of vincristine metabolism and neuropathy in pediatric acute lymphoblastic leukemia patients.

Amalia S Lehmann, BS

39G #9524-ABC drug transporter gene expression in neuroblastoma.

Samantha Cialfi

39H #9525-Use of loss of function RNA interference screen to evaluate TNK-2 as a factor involved in rhabdomyosarcoma cell growth.

Fernanda Irene Arnaldez

40A #9526-Genetic variants in *MDR1* and *CYP3A5* and vincristine toxicity in children with acute lymphoblastic leukemia.

Dunja Maroeslea W.M. Te Loo

40B #9527-Use of immunoglobulin heavy chain primer pools to assess minimal residual disease/persistent disease (MRD/PD) in children and adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL): A Children's Oncology Group report.

Bruce Shiramizu

40F #9528-Candidate serum biomarkers of doxorubicin-induced cardiotoxicity in pediatric acute lymphoblastic leukemia assessed by nanoparticle-capture mass spectrometry.

Emanuel Petricoin

40G #9529-A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora a kinase: A Children's Oncology Group Phase I Consortium study.

40H #9530-A pediatric phase I trial and pharmacokinetic study of aflibercept (VEGF Trap): A Children's Oncology Group Phase I Consortium study.

Julie R. Park

41A #9531-A multicenter, first-in-pediatrics phase I study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors.

Lia Gore

41B #9532-Phase I trial of lestaurtinib for children with refractory neuroblastoma (NB): A New Approach to Neuroblastoma Therapy (NANT) Consortium Study.

Jane E. Minturn

41C #9533-Phase II window of irinotecan plus carboplatin in newly diagnosed patients with rhabdomyosarcoma: Results of Memorial Sloan-Kettering Cancer Center (MSKCC) Protocol IRB 03-099.

Leonard H. Wexler

41D #9534-Cisplatin plus pirarubicin chemotherapy and combination ifomide, etoposide, pirarubicin, and carboplatin chemotherapy for hepatoblastoma.

Eiso Hiyama

41E #9535-Phase II trial of pemetrexed in children with refractory solid tumors: A Children's Oncology Group study.

Anne Benedicta Warwick

41F #9536-Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature B-NHL: A Children's Oncology Group report.

Mitchell S. Cairo, MD

41G #9537-A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric patients with refractory/recurrent Hodgkin Disease (HD): A Children's Oncology Group (COG) study.

Terzah M. Horton

41H #9538-Predicting an optimal strategy for insulin-like growth factor 1 (IGF1) signaling interference in Ewing's sarcoma (ES).

Addy C. M. van de Luitgaarden

- Discussion: New agents or combinations in childhood cancers

Frank M. Balis, MD

42A #9539-A pilot study using carboplatin, vincristine and temozolomide for children with progressive/symptomatic low-grade glioma: A Children's Oncology Group (COG) study.

Murali M. Chintagumpala

42B #9540-Phase I study of single-agent perifosine for recurrent pediatric solid tumors.

Oren J Becher

42C #9541-Phase II study of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma.

Birgit Geoerger

42D #9542-Hypothalamic/pituitary radiation exposure in low doses on fertility in female childhood cancer survivor study (CCSS) participants.

Daniel M. Green

- Discussion: Advances in CNS therapy

Mark W. Kieran, MD, PhD

Session Title: #199: Gastrointestinal (Colorectal) Cancer

Session Type: General Poster Session

Date: Sunday, June 6

Location: S Hall A2

Time: 2:00 PM - 6:00 PM

1A #3534-PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors.

Scott Kopetz, MD

1C #3536-Phase IB study of the src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer.

Christopher Hanyoung Lieu

1D #3537-Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC).

Michael B. Sawyer

1E #3538-Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC).

Niall Christopher Tebbutt

1F #3539-Phase II study of bevacizumab (B) plus oxaliplatin (Ox) plus capecitabine (C) followed by bevacizumab (B) plus erlotinib (E) as first-line treatment in metastatic colorectal cancer (mCRC).

Alberto Muñoz

1G #3540-Final analysis of the randomized trial of the German AIO CRC study group: Cetuximab plus XELIRI versus cetuximab plus XELOX as first-line treatment for patients with metastatic colorectal cancer (mCRC).

Nicolas Moosmann

1H #3541-Irinotecan/capecitabine (XELIRI) plus bevacizumab versus irinotecan/fluorouracil/leucovorin (FOLFIRI) plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A randomized phase III trial of the Hellenic Cooperative Oncology Group (HeCOG).

Dimitrios G. Pectasides

2A #3542-CAPIRI plus bevacizumab (CAPIRI-B) versus FOLFIRI plus bevacizumab (FOLFIRI-B) for the treatment of patients with metastatic colorectal cancer (mCRC).

Nikolaos Ziras

2B #3543-FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO).

Alfredo Falcone

2C #3544-Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983).

Haldan Sorbye

2D #3545-Panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Resections and curative surgery in a phase II single arm, multicenter study (20060314).

Ralf Hofheinz

2E #3546-Surgical cytoreduction in patients with colorectal peritoneal carcinomatosis treated with contemporary chemotherapy.

Vinicius G Gava

2F #3547-Outcome of 123 patients (pts) with peritoneal carcinomatosis (PC) & limited metastases from colorectal cancer (CRC) and appendiceal adenocarcinoma (ADC): The British Columbia Cancer Agency (BCCA) experience.

Francine Aubin

2G #3548-Outcome of colorectal liver metastases vanishing under chemotherapy and finally missing after surgery.

Sebastien Gaujoux

2H #3549-Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): Results of the phase II North Central Cancer Treatment Group study N054C.

Axel Grothey, MD

3A #3550-FEB study: Efficacy treatment evaluation in metastatic colorectal cancer (mCRC) patients (pts) changing monoclonal antibody (MA) after progression with chemotherapy.

Roberta Grande

3B #3551-CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) plus cetuximab (Cmab) in unselected advanced colorectal cancer (ACC) patients.

Carlo Garufi

3C #3552-Metronomic therapy irinotecan (IRI) capecitabine (CAP) plus bevacizumab (BEV) in treatment of advanced colorectal cancer (ACRC) in very elderly people.

Ignazio Ugo Carreca

3D #3553-Phase II trial alternating mFOLFOX 6 and FOLFIRI (FIREFOX) regimens in first-line treatment of advanced colorectal cancer in Japanese patients (KSCC 0701).

Yoshito Akagi

3E #3554-Analysis of prognostic factors for 60-day mortality: Evaluation of a randomized phase III trial investigating FUFIRI versus mIROX as first-line treatment of metastatic colorectal cancer (mCRC).

Clemens Giessen

3F #3555-Capécitabine (C) and bevacizumab (B) for nonresectable metastatic colorectal cancer (mCRC) patients: Results from phase II AIO 0105 trial.

Albrecht Kretzschmar

3G #3556-Incidence and risk factors for biliary sclerosis following adjuvant hepatic arterial infusion with floxuridine after hepatectomy for metastatic colorectal cancer.

Kaori Ito

3H #3557-A randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer.

Nancy E. Kemeny

4A #3558-Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (iv) fluorouracil (FU), leucovorin (LV), and cetuximab for first-line treatment of unresectable colorectal liver metastases (CRLM) (CHOICE): A multicenter phase II study.

David Malka

4B #3559-Unexpected increased biliary toxicity when systemic bevacizumab is added to hepatic arterial infusion.

Derek Gerard Power, Bsc, MD

4C #3560-Feasibility of neoadjuvant transarterial chemoembolization (TACE) using irinotecan beads (DEBIRI) before hepatectomy (HPX) for easily resectable colorectal liver metastases (RCLM): A phase II study.

Graeme John Poston

4D #3561-Premedication and incidence of infusion-related reactions in patients with metastatic colorectal cancer treated with cetuximab plus irinotecan-based chemotherapy.

Hansjochen Wilke

4E #3562-Use of germ-line polymorphisms in genes involved in the IGF pathway to predict efficacy of cetuximab independent of K-ras in mCRC patients (IMCL-0144).

Thomas Winder

4F #3563-Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in advanced rectal cancer.

Daniel Vallbohmer

4G #3564-Early magnesium modifications as a surrogate markers of efficacy of cetuximab based anticancer treatment in kras wild-type colorectal cancer patients.

Bruno Vincenzi

4H #3565^--Randomized phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second□line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis by tumor epidermal growth factor receptor (EGFR) staining.

Marc Peeters

5A #3566^--Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial analysis by epidermal growth factor receptor (EGFR) tumor staining.

Salvatore Siena

5B #3567-Beyond KRAS: The quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC).

Arjun Sood

5C #3568-Relationship between K-Ras mutational status and EGFR expression evaluated using Allred score in primary and metastatic colorectal cancer.

Elisa Melucci

5D #3569-Economic impact in the management of dermatologic toxicities (dTs) induced by the epidermal growth factor receptor inhibitor (EGFRI) cetuximab in colorectal cancer.

Judy H Borovicka, MD

5E #3570-Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of *KRAS* and *BRAF* biomarker status with treatment outcome.

Eric Van Cutsem

5F #3571-Impact of the amount of tumor cells in tissue samples for detection of *KRAS* mutations in colorectal cancer.

Janick Selves

5G #3572-*KRAS* mutation testing in patients with metastatic colorectal carcinoma: An 18-month experience emphasizing the risk of false-negative results.

Frédéric Bibeau

5H #3573-Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: *KRAS* mutation status and efficacy.

Benny Vittrup Jensen

6A #3574-Predictive role of carcinoembryonic antigen (CEA) for therapeutic efficacy of angiogenesis-targeting therapy in colorectal cancer: Novel clinical observation based upon recently discovered CEA biology.

Kira H. Bramswig

6B #3575-Bevacizumab-induced changes in small arterial dilatation measured in vivo by dynamic retinal vessel analysis.

Gunnar Folprecht

6C #3576-Gene expression profiles to predict outcome following liver resection in patients with metastasis of colorectal cancer.

Hirofumi Ito

6D #3577-Handy prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer.

Benoist Chibaudel, MD

6E #3578-Selecting colorectal cancer (CRC) patients for therapy based on mutational analysis by next generation sequencing: Are we analyzing the appropriate tumor?

Joost S Vermaat

6F #3579-Association between deficient mismatch repair system and efficacy to irinotecan containing first-line chemotherapy in patients with sporadic metastatic colorectal cancer.

Jeong-Eun Kim

6G #3580-Detector-c: A blood-based IVD with high sensitivity and specificity for early detection of colorectal cancer.

André Rosenthal

6H #3581-Correlation between bevacizumab-related hypertension and response in mCRC patients.

Alfonso De Stefano, MD

7A #3582-Personalized adjuvant chemotherapy for colorectal cancer based on an individual 50% inhibitory area under the concentration curve using collagen gel droplet embedded culture-drug sensitivity test.

Takumi Ochiai

7B #3583-Genetic polymorphism associated with chronic neurotoxicity and recurrence in curatively-resected colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.

Soo-Youn Lee

7C #3584-Are MGMT promoter methylation and EGFR mutations early markers of tumor progression in colorectal cancer?

Thomas Wenner

7D #3585-Prospective study of paresthetic neurotoxicity from oxaliplatin-based regimens in the treatment of colorectal cancer.

Xin Shelley Wang

7E #3586-Prognostic values of micrnas in patients with Dukes's B and C colon cancer.

Mihriban Karaayvaz

7F #3587-Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab in the first-line setting.

Angelos Koutras

7G #3588-New insights to gene expression signatures from primary FFPE tumors for the prediction of response to cetuximab in KRAS and BRAF wild-type colorectal cancer (CRC).

Eva Budinska

7H #3589-Analysis of EGFR pathway mediators in KRAS wild-type primary tumors is not representative of their status in related metastases.

Paloma Cejas

8A #3590-Association of GRP78 polymorphisms with response and TTP in patients with mCRC treated with FOLFOX/BV or XELOX/BV.

Heinz-Josef Lenz, MD

8B #3591-Lessons from PETACC 2: No prognostic impact of KRAS-/BRAF-status in stage III colon cancer treated with adjuvant 5-FU monotherapy.

Daniela Ellen Aust, MD

8C #3592-Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers.

Ben Tran

8D #3593-Number of lymph nodes examined and prognosis among pathologically node-negative patients after preoperative chemoradiation for rectal cancer.

C Jillian Tsai, MD, PhD

8E #3594-Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: Results of the ETNA cohort study.

Eric Terrebonne

8F #3595-Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS).

Tanios S. Bekaii-Saab, MD

8G #3596-Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP).

Allen Lee Cohn

8H #3597-Molecular classes in CRC: Characterization of MSI by expression profiling in the translational study of the PETACC 3-EORTC 40993-SAKK 60-00 trial.

Mauro Delorenzi, PhD

9A #3598-Impact of ethnicity and insurance on colorectal cancer outcomes.

Kristal B. Young

9B #3599-Use of day 4 CEP and baseline CXCR4 plus CEC as predictive markers for bevacizumab in mCRC.

Satoshi Matsusaka

9C #3600-Use of a four gene panel of epigenetic markers to classify serrated colonic adenomas with CpG island methylator phenotype.

Jenia Jenab-Wolcott

9D #3601-Prognostic factors for actual 5-year survivors after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal surface disease.

Perry Shen

9E #3602-Global microRNA expression and survival in patients with metastatic colorectal cancer in third-line treatment with cetuximab and irinotecan.

Jakob Vasehus Schou

9F #3603-Incidence of diagnosed VTE among elderly Americans in the year following stage III or IV colon cancer diagnosis.

C. Daniel Mullins

9G #3604-Venous thromboembolic events with chemotherapy plus bevacizumab: A pooled analysis of over 6,000 patients in randomized phase II and III studies.

James Cassidy

9H #3605-Adjuvant chemotherapy for colorectal cancer in the over 75 age group: A 10-year experience.

Richard M Bambury, MD

10A #3606-Predictors of lymph node count in colon adenocarcinoma.

Kellie Leanne Mathis

10B #3607-The number of lymph nodes is influenced by the MSI phenotype in resected colorectal cancers (CRC): A study in a large monocentric series.

Jean-François Flejou

10C #3608-Clinicopathologic factors and outcomes associated with lymph node retrieval in resectable colon cancer.

Swapna Kanuri

10D #3609-Clinicopathologic significance of p53, hypoxia-inducible factor 1 alfa, and vascular endothelial growth factor expression in colorectal cancer.

Hyuk-Chan Kwon

10E #3610-Mutation-based detection of molecular tumor margins in colorectal liver metastasis.

Kerstin Schmidt

10F #3611-Safety analysis of FOLFOX4 treatment in advanced/recurrent or adjuvant colorectal cancer in Asian and western patients.

Kenichi Sugihara

10G #3612-Predictor c: A tissue-based IVD predicting progression of disease in colorectal cancer UICC stages II or III.

André Rosenthal

10H #3613-Oxaliplatin- or irinotecan-based combination therapy versus 5-fluorouracil/leucovorin alone in the treatment of advanced colon cancer patients age 66 and older: An analysis using SEER-Medicare data.

Fei-Yuan Sharon Hsiao

11A #3614-Analysis of KRAS mutations in colorectal cancer (CRC) patients by gender in a Brazilian cohort of 3,346 patients.

Carlos G. M. Ferreira

11B #3615-Vitamin D levels and survival in colorectal cancer (CRC).

Kathleen Mary Wesa

11F #3616-Outcomes following adjuvant treatment (AT) for colon cancer (CC) 1978-1995 versus 1996-2007: Impact on recurrence rate, time from recurrence to death (TRD), and overall survival (OS)-Findings from the ACCENT dataset.

Thierry Andre

11G #3617-Genetic polymorphism and toxicity of adjuvant FOLFOX-4 chemotherapy in Korean colon cancer patients.

Hye Jung Chang

11H #3618-Reproductive history and risk of colorectal cancer in postmenopausal women.

Alice Zervoudakis

12A #3619-The effect of opposed versus unopposed hormone replacement therapy (HRT) on the risk of colorectal cancer (CRC).

Kueiyu Lin

12B #3620-Guideline adherence rates of chemotherapy treatment for colon cancer patients treated in U.S. community oncology practices.

Zhaohui Wang

12F #3621-Presurgical diagnostic accuracy of five imaging procedures in chemotherapy-naïve (group A) or chemotherapy-pretreated (group B) patients with colorectal liver metastases (Italian PROMETEO Study).

Fabiola Lorena Rojas Llimpe

12G #3622-Dietary grape-derived resveratrol for colon cancer prevention.

Micaela Martinez

12H #3623-Cost-effectiveness analysis of the addition of bevacizumab to first-line chemotherapy in metastatic colorectal cancer.

Diego Villa, MD, MPH

13A #3624-Association of survival outcomes with dose intensity of adjuvant therapy (AT) with capecitabine for colorectal cancer (CRC).

Jeremy Ho

13B #3625-Characterize medical care during disease phases in metastatic colorectal cancer.

Xue Song

13C #3626-Use of an electronic health record (iKnowMed), in conjunction with evidence-based pathways, for data capture and outcome measurement in colorectal cancer patients treated with first-line therapy in the US Oncology Network.

Thomas H. Cartwright

13D #3627-Spectrum of colon polyposis and colonic neoplasia in the PTEN hamartoma tumor syndrome (PHTS).

Peter P. Stanich

13E #3628-Treatment patterns in patients with colorectal liver metastasis: A cohort study.

Daniel A. Anaya

13F #3629-The awareness and knowledge levels of colorectal cancer (CRC) patients and their first-degree relatives (FDR) for CRC screening.

Cagatay Arslan

13G #3630-To detect Lynch syndrome patients, which colorectal cancers should be tested for microsatellite instability?

Bruce M. Boman

13H #3631-A novel, noninvasive, mRNA gene expression colon cancer screening methodology.

Lisa A Boardman, MD

14A #3632-Results of a German noninterventional study (NIS) of cetuximab-based therapy in pretreated patients (pts) with metastatic colorectal cancer (mCRC).

Christian Jehn

14B #3633-Timing of failure of resected rectal cancer: What is the appropriate duration of postoperative imaging?

Katherine Fischkoff

14C #3634-Preoperative chemoradiotherapy (QRTP) and total mesorectal excision (TME) by laparoscopy (LPS) in rectal cancer (RC): Long-term outcomes.

Estela Pineda

14D #3635-A randomized phase II trial of preoperative chemoradiotherapy with or without cetuximab in locally advanced adenocarcinoma of the rectum.

A. David McCollum

14E #3636-Preoperative chemoradiation (CRT) with concurrent capecitabine and irinotecan in MRI-defined locally advanced rectal cancer: Relationship of histologic downstaging to long-term survival end points.

Simon William Gollins

14F #3637-Chemotherapy induction followed by preoperative chemoradiation versus preoperative chemoradiation alone in locally advanced rectal cancer (LARC): A randomized controlled phase II study.

Raphaël Maréchal

14G #3638-Short-course radiation therapy, neoadjuvant bevacizumab, capecitabine and oxaliplatin, and radical resection of primary tumor and metastases in primary stage IV rectal cancer: A phase II multicenter study of the Dutch Colorectal Cancer Group.

Tonnis H. van Dijk

14H #3639-Effect of preoperative radiotherapy on local recurrences in rectal cancer patients with *PIK3CA* mutation.

Youji He

15A #3640-Association of intratumoral gene expression levels of thymidine phosphorylase (TP) and VEGF with clinical outcome in stage II/III rectal cancer patients treated with 5-fluorouracil and pelvic radiation in a phase III intergroup trial (SWOG 9304).

Robert D. Ladner

15B #3641-Use of EGF a+61G and TS-5'UTR 2R/3R polymorphisms to predict complete pathologic response in locally advanced rectal cancer patients undergoing preoperative cetuximab-based chemoradiation followed by surgery.

Siwen Hu-Lieskovan

15C #3642-Predictors of site-specific recurrence following combined modality therapy for locally advanced rectal cancer.

Pei-Rong Ding

15D #3643-Single nucleotide polymorphisms (SNPs) of hypoxia-related genes correlate with pathologic complete response (pCR) following neoadjuvant chemoradiation (chemoXRT) for locally advanced rectal cancer.

Motofumi Tanaka

15E #3644-Patterns of recurrence in rectal cancer treated with neoadjuvant chemoradiotherapy and TME.

David Liska

15G #3646-Local excision after neoadjuvant chemoradiation for rectal cancer: Is it an acceptable treatment option?

Baruch Brenner

15H #3647-Multimodal salvage therapy for locally recurrent and re-recurrent rectal cancer.

Y. Nancy You, MD, MHS

16A #3648-Plasma levels of total RNA and hTERT mRNA as biomarkers of response in rectal cancer patients receiving preoperative chemoradiotherapy.

Salvatore Pucciarelli

16B #3649-Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation.

Andrea Cercek

16C #3650-KRAS mutation status and clinical outcome of preoperative chemoradiation (CRT) with or without cetuximab in locally advanced rectal cancer (LARC): A pooled analysis of two phase II trials.

Sun Young Kim

16D #3651-Quantitative assessment of tumor cell density in rectal cancer following three different preoperative therapies compared to surgery alone.

Nicholas P West, MB, ChB, BSc

16E #3652-Relationship of completion of planned treatment and timing of adjuvant chemotherapy to survival in patients with colorectal cancer (CRC).

Shahid Ahmed

16F #3653-EGFR, PTEN, and survivin expression in pre- and posttherapeutic specimens does not predict a clinical benefit from preoperative chemoradiation with cetuximab in patients (pts) with locally advanced rectal cancer (LARC).

Kathrin Dellas

16G #3654-Evaluation of serum/plasma VEGF/e-selectin and 18F-FDG PET uptake after panitumumab infusion in locally advanced rectal cancer (LARC) patients treated with chemoradiation (CTRT) (StarPan/STAR-02 phase II study).

Sara Pini

16H #3655-Treatment of rectal carcinoid tumors and role of preoperative imaging.

Takayuki Akasu

17A #3656-Do older Americans undergo stoma reversal following low anterior resection for rectal cancer?

Christopher M. Dodgion

17B #3657-Bowel dysfunction after sphincter-preserving surgery.

Larissa K. F. Temple

17C #3658-The prognostic significance of tumor human papillomavirus status in patients with anal squamous cell carcinoma treated with combined chemoradiotherapy.

Ho-Young Yhim

Session Title: #200: Gastrointestinal (Noncolorectal) Cancer

Session Type: General Poster Session

Date: Sunday, June 6

Location: S Hall A2

Time: 2:00 PM - 6:00 PM

18A #4038-Linifanib phase II trial in patients with advanced hepatocellular carcinoma (HCC).

Han Chong Toh

18B #4039-Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer.

Milind M. Javle, MD

18C #4040-Clinicopathologic characteristics of microsatellite instability (MSI) tumors in resected gastric cancer patients.

Hyeon Jin Cho

18D #4041-Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle as second-line treatment for advanced or recurrent gastric cancer.

Keisho Chin

18E #4042-Meta-analyses of randomized trials assessing the effect of neoadjuvant chemotherapy in locally advanced gastric cancer.

Haoran Li

18F #4043-KRAS, BRAF mutations. and HER2 expression in patients operated for pancreatic adenocarcinomas.

Nicolai Aagaard Schultz

18G #4044-Prospective analysis of clinical outcomes and prognostic factors in patients with neuroendocrine tumors (NETs).

Monica Ter-Minassian

18H #4045-Comparative effectiveness of radioembolization and the standard of care for hepatocellular carcinoma: Is a randomized survival study feasible?

Riad Salem, MD, MBA

19A #4046-Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study.

Ahmed Omar Kaseb

19B #4047-Association of germline polymorphisms in genes involved in the CD44 pathway and clinical outcome in localized gastric adenocarcinoma (GA).

Yan Ning

19C #4048-(Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer.

Hyun Cheol Chung, MD, D.Phil.

19D #4049-Setting the standard for advanced pancreatic ductal adenocarcinoma (A-PDAC) in 2010: Meta-regression and power analysis of phase III randomized clinical trials (RCT) evaluating gemcitabine (GEM) in combination with cisplatin (CIS), oxaliplatin (L-OHP), or capecitabine (CAP).

Isabella Sperduti

19E #4050-Final results of a phase II study of modified FOLFOX6 (mFOLFOX6) and erlotinib (E) in patients with metastatic adenocarcinoma of the esophagus (Eso) and gastroesophageal junction (GEJ).

Zev A. Wainberg

19F #4051- Efficacy and safety of sorafenib (Sor) in patients (Pts) with advanced hepatocellular carcinoma (HCC): Subgroup analyses of the SHARP trial by baseline (BL) transaminase (ALT/AST)/ α -fetoprotein (AFP) and bilirubin (bil) levels.

Jean-Luc Raoul

19G #4052-Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407).

Hiroya Takiuchi

19H #4053-A multicenter randomized phase II (rPII)/ III study comparing concurrent chemoradiotherapy (CRT) with low-dose cisplatin plus continuous infusion of 5-fluorouracil (LDPF) and standard-dose PF (SDPF) for locally advanced unresectable squamous cell carcinoma of the thoracic esophagus (JCOG0303).

Masayuki Shinoda

20A #4054-Association of germline polymorphism in the SPARC gene and tumor recurrence in patients with resected gastric cancer.

Peter M.D. Wilson

20B #4055-Ten-year experience of percutaneous radiofrequency ablation for hepatocellular carcinoma.

Shuichiro Shiina

20C #4056-An analysis of the effect of smoking status on erlotinib pharmacokinetics (PKs), toxicity, and ability to dose escalate in a phase II study of erlotinib in advanced pancreatic cancer (PC).

Daniel John Renouf

20D #4057-Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer.

Taroh Satoh

20E #4058-A multicenter phase II trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.

Tatsuya Ishii

20F #4059-Effect of hyperacute immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer on disease-free and overall survival: Preliminary analysis of phase II data.

Jeffrey M Hardacre, MD

20G #4060-Randomized phase II trial with an uPA inhibitor (WX-671) in patients with locally advanced nonmetastatic pancreatic cancer.

Volker Heinemann

20H #4061-Survival prolongation after treatment failure in patients with advanced gastric cancer (AGC): Results from combined analysis of JCOG9205 and JCOG9912.

Atsuo Takashima

21A #4062-A single-institution (MSKCC) analysis of incidence and clinical outcomes in patients with thromboembolic events and exocrine pancreas cancer.

Andrew S. Epstein

21B #4063-Prognostic values of baseline circulating endothelial progenitor level for advanced hepatocellular carcinoma (HCC) patients under antiangiogenic therapy.

Yu Yun Shao

21C #4064-E2205: A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy (CRT) with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab (C) followed by postoperative docetaxel (DT) and C in patients with operable adenocarcinoma of the esophagus.

Michael K. Gibson

21D #4065-Prognostic significance of xCT gene single nucleotide polymorphisms (SNPs) in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (GEM) plus platinum analogues (PLAT).

Tzu-chuan Jane Huang

21E #4066-Sorafenib plus chemotherapy versus chemotherapy alone in advanced pancreatic cancer: A randomized phase II trial.

Stefano Cascinu

21F #4067-Significance of pathologic response to preoperative therapy in pancreatic cancer.

Yun Shin Chun, MD

21G #4163-A phase II clinical trial of MK-0646, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), in patients with metastatic well-differentiated neuroendocrine tumors (NETs).

Diane Lauren Reidy

21H #4069-Predictive value of restaging after induction concurrent chemoradiotherapy (CCRT) for locoregionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastroesophageal junction (GEJ).

Brooke E Phillips

22A #4070-Trastuzumab and capecitabine in patients with HER2-expressing metastatic pancreatic cancer: A multicenter phase II study of the German AIO Pancreatic Cancer Group (AIO PK-0204).

Michael Geissler

22B #4071-Is minimally invasive esophagectomy for cancer decreasing pulmonary complications? Results from a case-control study.

Nicolas Briez

22C #4072-Multicenter phase II study of SIR-sphere plus sorafenib as first-line treatment in patients with nonresectable hepatocellular carcinoma: The Asia-Pacific Hepatocellular Carcinoma Trials Group Protocol 05 (AHCC05).

Pierce KH Chow, MD, PhD

22D #4073-Phase II trials (P2T) in advanced pancreatic cancer (APC): Systematic review with focus on the design, entry criteria, and endpoints used.

Anastasios Stathis

22E #4074-Extended safety and efficacy data on triple combination therapy using s-1, cisplatin, and paclitaxel in patients with advanced gastric cancer in a multicenter phase II study.

Hiroaki Iwase

22F #4075-Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: Safety and response results from a multicenter phase II trial.

Lorenzo E Ferri

22G #4076-A phase II randomized double blind multicenter trial of gemcitabine (Gem) plus imexon (IMX) versus Gem plus placebo (P) in patients with chemotherapy-naïve pancreatic adenocarcinoma (PC).

Steven J. Cohen

22H #4077-The impact of socioeconomic status upon specialist consultation, treatment, and outcomes for pancreatic adenocarcinoma.

James E Carroll

23A #4078-Registry of Gastric Cancer Treatment Evaluation (REGATE): Regional differences in surgical approaches.

Mikhail Ter-Ovanesov

23B #4079-Comorbidity and overall survival (OS) in patients with advanced pancreatic cancer (APC): Results from NCIC CTG PA.3-A phase III trial of erlotinib plus gemcitabine (E+G) versus gemcitabine (G) alone.

Michael M. Vickers

23C #4080-Hereditary gastric cancer caused by germline CDH1 gene mutations in the Netherlands.

Irma Kluijt

23D #4081-Early toxicity of sunitinib as a potential predictive biomarker in advanced hepatocellular carcinoma (HCC) patients.

Gabriel Dan Duda

23E #4082-Registry of Gastric Cancer Treatment Evaluation (REGATE): Geographic analysis of baseline characteristics of 10,124 patients (pts).

John Raymond Zalcborg

23F #4083-A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC).

Andrew X. Zhu

23G #4084-Prognostic significance of cell cycle regulating protein expressions in gastric carcinoma patients receiving adjuvant chemotherapy.

Young Soo Park

23H #4085-Neoadjuvant paclitaxel poliglumex (PPX), cisplatin, and radiation (RT) for esophageal cancer.

Thomas Ng

24A #4086-Phase II trial of ixabepilone (IXA) plus cetuximab (C) as first-line therapy for advanced pancreatic carcinoma (PC).

Caio Max S. Rocha Lima

24B #4087-Outcome of patients with recurrent hepatocellular carcinoma after liver transplantation.

Armin Finkenstedt

24C #4088-Relapse of hepatocellular carcinoma (HCC) after liver transplantation (LT): A single-center analysis on 139 patients in the sorafenib era.

Tulio Eduardo Flesch Pfiffer

24D #4089-Survival of complete responder patients treated for esophageal cancer with chemoradiotherapy followed by surgery as compared to chemioradiotherapy alone: Case-control study.

Mathieu Messager

24E #4090-Registry of Gastric Cancer Treatment Evaluation (REGATE): Staging and diagnosis of 10,124 patients (pts).

Chew-Wun Wu

24F #4091-FOLFOX6 as first-line treatment in metastatic gastric cancer: Preliminary results of a phase II trial.

Annalisa Fontana

24G #4092-Outcome prediction in hepatocellular carcinoma (HCC): Comparison of alphafetoprotein (AFP) response and conventional radiologic criteria during sorafenib treatment.

Nicola Personeni

24H #4093-Association of human epidermal growth factor receptor 2 (HER2) Ile655Val polymorphism (plrm) and gender-specific time to tumor recurrence (TTR) in patients (pts) with localized gastric adenocarcinoma (GA).

Edwin Yung-Mu Lin, MD

25A #4094-A phase II, open label study to evaluate the relationship between skin rash and survival in patients with unresectable and/or metastatic pancreatic cancer treated with erlotinib combined with gemcitabine.

Jose Luis Manzano

25B #4095-Association between smoking history and disease-free and overall survival in resected gastric cancer.

Elizabeth Catherine Smyth

25F #4096-Optimal assessment of treatment benefit with targeted agents for hepatocellular carcinoma (HCC): An analysis of brivanib phase II data.

Richard S. Finn

25G #4097-A phase I dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.

SuPin Choo

25H #4098-Association between DNA repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy.

Paola Pacetti

26A #4099-Docetaxel, oxaliplatin, and capecitabine (TEX Regimen) in patients with advanced or metastatic gastric or gastroesophageal cancer (GC): Results from a phase II trial of the German AIO group.

Dirk Arnold

26B #4100-Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): Preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP), and radiation (RT) for esophageal cancer (EC).

Nikhil I. Khushalani

26F #4101-Role of IL-6 in cachexia progression in advanced pancreatic cancer.

Shuichi Mitsunaga

26G #4102-Treatment of advanced or metastatic hepatocellular cancer (HCC): Interim analysis of a single- arm phase II study of bevacizumab and RAD001.

Gerhard Treiber

26H #4103-HER2 status of gastric and gastroesophageal cancer (GC) patients assessed by immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and high-resolution array comparative genomic hybridization (aCGH).

Yelena Yuriy Janjigian

27A #4104-A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors.

Pamela L. Kunz

27B #4105-Utility of post-treatment FDG-PET in predicting outcomes in anal cancer managed with chemoradiotherapy.

Alexander Graham Heriot

27C #4106-Concurrent chemoradiotherapy with cetuximab plus twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.

Chih-Hung Hsu

27D #4107-Phase II study of cetuximab in combination with modified FOLFIRI in patients with advanced gastric cancer who failed first-line chemotherapy (EFFI study).

Jin Li

27E #4108-A phase II trial of preoperative chemoradiation therapy plus bevacizumab and erlotinib in the treatment of localized esophageal cancer.

Anthony Alan Meluch

27F #4109-Overall survival and clinically deficient quality of life in patients with esophageal cancer or Barrett's esophagus: A Mayo Clinic esophageal adenocarcinoma and Barrett's Esophagus Registry consortium study.

Robert Clell Miller

27G #4110-Somatostatin analogue therapy and PROMIS health-related quality-of-life scores in patients with neuroendocrine tumors.

Mei Dong

27H #4111-Impact of a novel inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: A retrospective study of 398 Japanese patients.

Mitsuru Ishizuka

28A #4112-Intensity-modulated radiotherapy for esophageal cancer: Analysis of toxicity and outcomes.

Naamit Kurshan

28B #4113-Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms.

Vanja Vaccaro

28C #4114-Is diabetes mellitus (DM) associated with worse outcomes in pancreatic cancer (PC)?

Olugbenga O Olowokure, MD, MBBS

28D #4115-Therapeutic effects of fractionated radioimmunotherapy (RAIT) with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC).

Allyson J. Ocean

28E #4116-Docetaxel, cisplatin, and capecitabine (DCX) as perioperative chemotherapy in gastroesophageal adenocarcinoma: A phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Peter C. Thuss-Patience

28F #4117-Association of diabetes with perineural invasion and overall survival in surgically resected patients with pancreatic cancer.

Mohamed Ahmed Shama

28G #4118-Registry of Gastric Cancer Treatment Evaluation (REGATE): Variations in nonsurgical therapies.

Suayib Yalcin

28H #4119-Diagnostic value of Lens culinaris agglutinin isoform 3 fraction (AFP-L3%) and des-gamma-carboxy prothrombin (DCP) for the diagnosis of hepatocellular carcinoma in cirrhotic patients.

Raffaella Romeo

29A #4120-A phase II trial of nab-paclitaxel (NP) in patients with advanced pancreatic cancer (PC) who have progressed on gemcitabine(G)-based therapy.

Peter Joel Hosein

29B #4121-*Helicobacter pylori* infection as an independent prognostic factor for locally advanced gastric cancer with curative resection.

Seok Yun Kang

29C #4122-Results of a phase II multicenter study of neoadjuvant s-1 and irinotecan in patients with locally advanced gastric cancer.

Masanori Terashima

30A #4123-Prognostic markers for response and overall survival in patients with esophageal adenocarcinoma treated with neoadjuvant therapy.

Jessica M. Leers

30B #4124-Early outcome of phase II study of preoperative chemotherapy (CX) with s-1 plus cisplatin for stage IV gastric cancer (StIV GC).

Seiji Satoh, MD, PhD

30C #4125-Cost-effectiveness of neoadjuvant (NeoAdj) versus adjuvant (Adj) therapies for resectable pancreatic cancer (PC).

Rachna T. Shroff

31A #4126-Association of elevated tissue factor (TF) with survival and thromboembolism (TE) in pancreaticobiliary cancers (PBC).

Anubha Bharthuar

31B #4127-Characterization and prognostic significance of circulating tumor cells in the peripheral blood of patients with metastatic pancreatic cancer.

Benjamin P. Negin

31C #4128-Use of tumor arterial perfusion assessment and RECIST for prediction of survival and residual disease in hepatocellular carcinoma following intra-arterial infusion chemotherapy.

John R. Daniels

32A #4129-Analysis of D7S486 in primary gastric cancer and evaluation of TESTIN as a candidate tumor suppressor gene.

Jianchuan Xia

32B #4130-Dynamic changes in age, stage distribution, and survival of patients with esophageal adenocarcinoma over three decades in the United States.

Putao Cen

32C #4131-Identification of three potential biomarkers in early resectable hepatocellular carcinoma.

Soo Fan Ang

33A #4132-Clinical outcomes and survival in patients with hepatocellular carcinoma and HIV infection.

Massimiliano Berretta

33B #4133-Analysis of biomarker expression (ki67, EGFR, HER-2, ERK, NFkB, and mTOR) in patients with advanced gastric and gastroesophageal junction (GEJ) cancer treated with cetuximab plus cisplatin/docetaxel: DOCETUX study.

Carmine Pinto

33C #4134-A phase I dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy-naive metastatic pancreatic cancer.

Massimo Aglietta

34A #4135-Clinical outcome of local recurrence cases after endoscopic mucosal resection (EMR) for Japanese Classification stage 0 esophageal cancer.

Takako Yoshii

34B #4136-A phase I study, with expanded cohort, of biweekly fixed-dose rate gemcitabine (FDR GEM) plus capecitabine (CAP) in patients with advanced pancreatic (APC) and biliary carcinomas (ABC).

Anne Marie Espinoza

34C #4137-Final results from ARQ 197-114: A phase 1b safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC).

Paolo Zucali

35A #4138-The utility of PET/CT in the treatment management of gastroesophageal cancer (GEC): Impact on staging and treatment decisions.

Wen Wen Shan

35B #4139-Phase I study of sorafenib (S) with gemcitabine (G)-based radiotherapy (G-RT) in patients (pts) with locally advanced unresectable pancreatic adenocarcinoma (LAUPC).

Stephen Anderson

35C #4140-Use of serum VEGF (SVEGF) levels to predict outcome of esophageal cancer (EC) patients undergoing preoperative chemoradiation (CRT).

Fernando De Vita

35D #4141-Chemoembolization with epirubicin drug-eluting beads (DEB-TACE) to treat early and intermediate hepatocellular carcinoma.

Antonio Nicolini

35E #4142-Dose-dense chemotherapy (CT) with modified dose-dense TCF regimen (TCF-dd) in metastatic gastric cancer (MGC): Update of a phase II study.

Matteo Dalla Chiesa

35F #4143-Phase II study of oxaliplatin, high-dose capecitabine, and sorafenib in patients with advanced pancreatic cancer.

Sam Joseph Lubner

35G #4144-Dose-painted intensity-modulated radiation therapy for anal cancer: A multi-institutional report of acute toxicity and response to therapy.

Theodore S. Hong, MD

35H #4145-A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer.

Eiichiro Suzuki

36A #4146-Upregulation of multidrug resistance-associated protein 4 in the early stage of vascular invasion of hepatocellular carcinoma.

Keishi Higuchi

36B #4147-A feasibility analysis from the patient preference randomized phase III clinical trial of second-line chemotherapy (SLC) in advanced gastric cancer (AGC) patients pretreated with both fluoropyrimidines and platinum.

Se Hoon Park

36C #4148-Prediction of prognosis in hepatocellular carcinoma based on a gene signature from highly tumorigenic liver cancer cells.

Xin-Rong Yang

36D #4149-Phase I and II studies of intravenous Regin-G as monotherapy for stage IVb gemcitabine-resistant pancreatic cancer.

Howard Bruckner

36E #4150-Phase II study of FOLFIRI chemotherapy as first-line treatment for elderly patients (pts) with advanced gastric cancer (AGC).

Yves Becouarn

36F #4151-Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in pts with cancer of unknown primary site (CUP).

Gauri R. Varadhachary, MD

36G #4152-Clinical outcomes in pancreatic adenocarcinoma (PAC) in breast cancer (BC) survivors.

Maeve Aine Lowery

36H #4153-Phase II trial of gemcitabine (G), oxaliplatin (O), and erlotinib (T) for the treatment of hepatocellular carcinoma (HCC) and biliary tree cancers (BTC).

Yehuda Z. Patt

37A #4154-Maruyama index (MI) and outcomes of gastric cancer resection.

Jasjit C. Sachdev

37B #4155-A dose-escalation study of gemcitabine (Gem) plus oxaliplatin (Ox) in combination with imatinib in patients (pts) with gemcitabine-refractory advanced pancreatic adenocarcinoma (PC).

Naureen Starling

37C #4156-Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric cancer undergoing a potentially curative resection.

Sylvie Lorenzen

37D #4157-Phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin (POF) in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.

Rongb-Bo Lin

37E #4158-Role of MT1-MMP and Kras in invasive pancreatic tumors with pronounced fibrosis.

Seth B. Krantz

37F #4159-Lenalidomide for advanced hepatocellular cancer (HCC) in patients progressing on or intolerant to sorafenib.

Howard Safran

37G #4160-Analysis of four human PIGF isoforms and of VEGFR-1 in esophageal carcinoma.

Alexander Schultze

37H #4161-A phase I/II study of photodynamic therapy (PDT) using HPPH for the treatment of Barrett's and precancerous lesions of the esophagus.

Hector R Nava

38A #4162-Tumoral and angiogenesis factors in hepatocellular carcinoma (HCC) after drug eluting bead (DEB) transarterial chemoembolization (TACE) with doxorubicin.

Alton B Farris

Session Title: #211: Pediatric Oncology

Session Type: General Poster Session

Date: Sunday, June 6

Location: S Hall A2

Time: 2:00 PM - 6:00 PM

43A #9543-Phase I trial of oxaliplatin and doxorubicin in children and adolescents with recurrent solid tumors.

Leo Mascarenhas

43B #9544-A phase I trial of continuous hyperthermic peritoneal perfusion using cisplatin in pediatric patients with carcinomatosis.

Andrea Anita Hayes-Jordan

43C #9545-Pilot study of the novel chemotherapy regimen of topotecan, ifosfamide, and carboplatin (TIC) in children with refractory/recurrent solid tumors.

Alice Lee

43D #9546-Dose-finding study by continuous reassessment method (CRM) for topotecan (TT) in combination with ifosfamide (IF) as a second-line therapy for pediatric solid cancer: Preliminary report of phase I/II study.

Hiroshi Kawamoto

43E #9547-An investigator-initiated registration-directed phase I/II clinical trial of irinotecan hydrochloride for refractory pediatric solid tumors.

Atsushi Makimoto

43F #9548-Simulations of cilengitide PK profiles in pediatric population by means of allometric scaling: Reliability and support to BSA-based dose adjustment strategy.

Michael Zuehlendorf

43G #9549-Intensity-modulated radiation therapy for pediatric head and neck rhabdomyosarcoma: French preliminary results.

Julie Leseur

43H #9550-Sorafenib, gamma-secretase inhibitor, and bortezomib as potential therapeutic agents for hepatoblastoma.

Patricia C Sanchez-Diaz

44A #9551-Late side effects of neoadjuvant chemotherapy in patients treated for osteosarcoma and Ewing's sarcoma: An Italian Sarcoma Group study.

Alessandra Longhi

44B #9552-Feasibility of bevacizumab (NSC 704865, BB-IND# 7921) combined with vincristine, topotecan, and cyclophosphamide in patients with first recurrent Ewing sarcoma (EWS): A Children's Oncology Group (COG) study.

Patrick Leavey

44C #9553-Long-term results of expandable endoprosthesis replacement in children with malignant bone tumors.

Wojciech Woźniak

44D #9554-Long-term neurocognitive outcomes in adult survivors of childhood medulloblastoma.

Kim Edelstein

44E #9555-Premature deaths and severe morbidity in 192 long-term survivors of pediatric optic pathway tumors (OPT): A 50-year study.

Emilie De Carli

44F #9556-Medulloblastoma histological variants as the most powerful prognostic indicator: A 10-year mono-institutional experience.

Maura Massimino

44H #9558-Improved collaboration and clinical trial enrollment in adolescent and young adult (AYA) oncology patients after the establishment of an AYA program.

Peter H Shaw

45A #9559-Survival by race among children with extracranial solid malignancies.

Kelsey Johnson

45B #9560-Physician preferences and knowledge gaps regarding the care of childhood cancer survivors: A survey of ASCO oncologists.

Mackenzie Kigin

45C #9561-Allogeneic stem cell transplantation from HLA identical donor in high risk sarcoma

Franca Fagioli

45D #9562-Reduced intensity conditioning regimen and allogeneic stem cell transplantation from related or unrelated HLA identical donor in high risk neuroblastoma.

Arcangelo Prete

45E #9563-Tandem stem cell transplantation as consolidation therapy for high risk neuroblastoma: The Children's Healthcare of Atlanta experience.

Muna Qayed

45F #9564-STAT3 as a molecular target in pediatric t-cell leukemia.

Jixin Ding

45G #9565-Activity of the heat shock protein 90 (HSP90) inhibitor, SNX-2112, in pediatric cancer cell lines.

Danielle C. Chinn

45H #9566-Effect of bortezomib on ER stress and killing of cisplatin-resistant U2OS osteosarcoma cell line.

Wei-hong Zhao

46A #9567-Modulation of MET with the small molecule inhibitor PF-04217903 might result in decreased osteosarcoma metastasis in vivo.

Lisa M Niswander

46B #9568-GD2 expression in tumorspheres from neuroblastoma cell lines and in tumor-initiating cells derived from patient samples.

Adrienne Marie Hammill

46C #9569-Effect of all-trans retinoic acid on proliferation of human rhabdomyosarcoma and remission in an in vivo mouse xenograft model.

Raya Hamad Saab

46E #9571-Plasma fractionated total metanephrines for biochemical diagnosis of neuroblastoma.

Laura Crosazzo Francini

46F #9572-A prospective trial of prophylaxis and treatment (P+T) of acute tumor lysis syndrome (ATLS) with rasburicase (R) and nonalkaline hydration in children and adolescents (C+A) with intermediate- (Group B) and high-risk (Group C) mature B-NHL: A Children's Oncology Group report.

Stanton Goldman

46G #9573-High-dose methotrexate in the treatment of acute lymphoblastic leukemia: Toxicity profile and comparison of tolerability between two dosage schedules.

Arun Rajagopal Warriar

46H #9574-T-cell lymphoblastic lymphoma in children and adolescents: The experience of the Israel Society of Pediatric Hematology Oncology.

Myriam Weyl Ben Arush

47A #9575-Risk-based outcome of childhood AML: Experience of National Guard Hospital, Jeddah, Saudi Arabia.

Wasil A Jastaniah

47B #9576-High frequency of Gilbert's syndrome in ETV6/RUNX1-positive childhood acute lymphoblastic leukemia (ALL): Implications for etiology.

Yaddanapudi Ravindranath

47C #9577-*Clostridium difficile* infection among children with cancer.

Eric Tai

47D #9578-Iterative anesthesia for radiation therapy in pediatric oncology: Safety of a procedure using propofol alone.

Henri Sebban

47E #9579-Diagnosis of invasive fungal infections by RQ-PCR assay in pediatric acute leukemia induction.

Sushil Mandhaniya

47F #9580-Clinical pharmacokinetics (PK) and safety of high-dose (HD) methotrexate (MTX) during induction therapy of pediatric patients younger than 3 years of age with primary brain tumors.

Trevor McKibbin

47G #9581-Criteria defining the duration of chemoreduction with focal treatment in retinoblastoma: A retrospective analysis.

Maja Beck Popovic

Session Title: #212: Sarcoma

Session Type: General Poster Session

Date: Sunday, June 6

Location: S Hall A2

Time: 2:00 PM - 6:00 PM

48A #10034-Prognostic value of the most frequent mutations in GIST: Results of the French population-based prospective study MolecGIST.

Jean-François Emile

48B #10035-Combination of targeted therapy (imatinib) with immunotherapy (peginterferon α-2b) to overcome drug resistance and tumor stem cells in gastrointestinal stromal tumors (GIST).

Lei L. Chen

48C #10036-Phase I/II study of TH-302 combined with doxorubicin in soft tissue sarcoma.

Lee D. Cranmer

48D #10037-Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An EORTC Soft Tissue and Bone Sarcoma Group randomized phase II study.

Hans Gelderblom

48E #10038^--Multicenter, triple-arm, single-stage, phase II trial to determine the efficacy and safety of everolimus (RAD001) in patients with refractory bone or soft tissue sarcomas including GIST.

Stephan Richter

48F #10039-Identification of oncogenic events in gastrointestinal stromal tumors (GISTs) by combined gene expression and copy number analysis.

Margherita Nannini

48G #10040-Soluble factors (SF) associated with efficacy and toxicity of pazopanib (PZB) in advanced soft tissue sarcoma (STS) patients (pts): An EORTC-STBSG study.

Stefan Sleijfer

48H #10041-Radiofrequency ablation of lung metastases arising from sarcoma.

Jean Palussiere

49A #10042-Improvement in the survival for adult soft tissue sarcoma with adjuvant anthracycline chemotherapy combination: A meta-analysis and metaregression.

Sergio L Afonso, MD

49B #10043-BRAF V600E mutations in benign and malignant peripheral nerve sheath tumors.

Cesar Serrano

49C #10044-Use of a genome-wide single nucleotide polymorphism array-based chromosomal analysis to evaluate uniparental disomy (UPD) in gastrointestinal stromal tumors (GIST).

Nelson Lourenço

49D #10045-Trends in survival for metastatic soft-tissue sarcoma: A French Sarcoma Group (GSF) database analysis.

Antoine Italiano

49E #10046-Novel reconstruction using tumor-containing autologous bone grafts frozen in liquid nitrogen.

Hiroyuki Tsuchiya

49F #10047-Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib (IM).

Buu-Phuc Nguyen

49G #10048^--Multicenter, single-arm, two-stage phase II trial of everolimus (RAD001) with imatinib in imatinib-resistant patients (pts) with advanced GIST.

Peter Hohenberger

49H #10049-Targeting CHK1 pathway to induce cytotoxic response to histone deacetylase inhibitors and evaluating the synergistic effects of CHK1 and HDAC inhibitors in human soft tissue sarcoma cell lines and primary tumor xenografts.

Damon R. Reed

50A #10050-CSPG4 and B7-H3 as prognostic biomarkers in chordoma.

Andrew Schoenfeld

50B #10051-Outcome of patients (pts) with PDGFRAD842V mutant gastrointestinal stromal tumor (GIST) treated with imatinib (IM) for advanced disease.

Pierre Biron

50C #10052-Coexistence of gastrointestinal stromal tumor (GIST) with desmoid tumor (DT): Case series of 22 patients.

Amaury Gerard Dumont

50D #10053-Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumor (GIST).

Oluwatojin Oladeji

50E #10054-Development of a nomogram to predict overall survival in patients with locally advanced or metastatic gastrointestinal stromal tumor receiving first-line treatment with imatinib.

David Goldstein

50F #10055-Gastrointestinal stromal tumor (GIST) of the rectum and pararectal space: A French Sarcoma Group (FSG) retrospective review.

Florence Duffaud

50G #10056-Surgery of residual disease of myxoid liposarcoma (MLS) patients responding to trabectedin.

Roberta Sanfilippo

50H #10057-Quality of randomized controlled trials reporting in the treatment of sarcomas.

Maud Toulmonde

51A #10058-Antiproliferative effect of mTOR inhibitor everolimus (EV) alone or in combination with multikinase inhibitor (MK-I) sorafenib (SOR) in preclinical models of osteosarcoma (OS).

Ymera Pignochino

51B #10059-Sunitinib (SU)-related hypertension in a randomized placebo (P)-controlled trial of GIST patients (pts).

Michael Ewer

51C #10060-A phase II trial of imatinib (IM) in relapsed, nonresectable chondrosarcoma (CS) expressing platelet-derived growth factor receptor- α ; or - β ; (PDGFR- α ;/PDGFR- β ;): An Italian Sarcoma Group study.

Giovanni Grignani

51D #10061-Adjuvant imatinib therapy of 208 gastrointestinal stromal tumor (GIST) patients: Dose, duration, and risk assessment.

Jonathan C. Trent

51E #10062-Quality of life (QoL) in osteosarcoma: First results of the presurgery treatment period of EURAMOS-1 (NCT00134030).

Andreas Wiener

51F #10063-High-dose photon-beam radiation therapy in chordoma: A single institution retrospective analysis.

Claudia Sangalli

51G #10064-Impact of imatinib plus best supportive care in imatinib and sunitinib exposed patients with refractory advanced gastrointestinal stromal tumor.

Akira Sawaki

51H #10065-Metronomic oral cyclophosphamide (CPM) and prednisolone in elderly patients (pts) with inoperable or metastatic soft tissue sarcoma (STS).

Olivier Mir

52A #10066-*PAX3/7-FOXO1* fusions by fluorescent in situ hybridization (FISH) using an adult rhabdomyosarcoma tissue microarray.

Sarah N. Dumont

52B #10067-Cutaneous angiosarcoma of the head and neck.

Prakash K Pandalai

52C #10068-Quality of surgical margins and local recurrence in primary extremity soft tissue sarcoma (STS).

Sylvie Bonvalot, MD, PhD

52D #10069-Immunohistochemical study and fluorescent in situ hybridization analysis of *JAZF1* in 67 cases of endometrial stromal tumors collected in a tissue microarray.

Juliette Duclos

52E #10070-Prognostic factors of *KIT*-negative GIST-like patients (KNGL): A Spanish Group for Sarcoma Research (GEIS) study.

Javier Martin Broto

52F #10071-Absence of correlation between the molecular subtype of *COL1A1-PDGFB* fusion gene and the clinico-histopathological features of dermatofibrosarcoma protuberans: Analysis of 35 novel cases and review of 137 cases from the literature.

Damien Giacchero

52G #10072-Nonstandard dosing in gastrointestinal stromal tumors: A registry observation.

Peter W. T. Pisters

52H #10073-Imaging-guided core needle biopsies (CNB) compared to surgical biopsies (SB) for soft tissue tumors: A cost-effectiveness analysis.

Sophie Taieb

53A #10074-First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histologic soft tissue sarcoma (STS) subtypes and as a prognostic factor for MPNST: An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) study.

Judith R. Kroep

53B #10075-First report of outcomes with neoadjuvant chemoradiotherapy (NCR) using weekly intravenous (IV) cisplatin with radiation (NCWR) for treatment of stage II and III extremity soft tissue sarcoma (STS).

Kelly Kevelin Curtis

53F #10076-Antitumor activity of pemetrexed (Pem) in second-line advanced/metastatic osteosarcomas: A multicenter phase II study.

Nguyen Bin Bui

53G #10077-Evaluation of quality of life in patients treated with resection and reconstruction of the upper or lower limb for bone sarcomas.

Pietro Ruggieri

53H #10078-Prognostic significance of proliferation markers and telomerase activity in gastrointestinal stromal tumors.

Alena Augustinakova

54A #10079-Effect of adjuvant radiotherapy on survival in localized limb or trunk wall well-differentiated liposarcoma (WDLPS).

Aude Duret

54B #10080-Efficacy of neoadjuvant doxorubicin and ifosfamide (AI) in myxoid /round cell liposarcoma (MRCL): The M.D. Anderson Cancer Center experience (MDACC).

Daniela Katz

54F #10081-Assessment of early response to imatinib 800 mg after 400 mg progression by 18 f-fluorodeoxyglucose positron emission tomography in patients with metastatic gastrointestinal stromal tumor.

Adriel Rodriguez Espíndola

54G #10082-Effect of radiation therapy on survival of patients with surgically resected retroperitoneal sarcoma: A population-based matched pair study.

Audrey Choi, BA

54H #10083-Sunitinib as the second-line therapy for advanced GISTs after failure of imatinib in Korean patients.

Min-Hee Ryu

55A #10084-Gastrointestinal stromal tumors (GISTs) and other cancers: Cambridge GIST Study Group experience.

Venkata Ramesh Bulusu, MBBS, MSc, MD

55B #10085-Impact of subspecialty, clinical volume, and years of practice in selection of treatment sequencing in the management of localized extremity soft tissue sarcoma.

Robert J. Canter

55C #10086-Pattern of growth of retroperitoneal sarcoma: Do they push or infiltrate adjacent organs? Analysis of a single institution series.

Chiara Erminia Mussi

55D #10087-Neoadjuvant, adjuvant, and palliative treatment with imatinib in patients with gastrointestinal stromal tumors.

Bengt E Nilsson

55E #10088-Long-term results of primary re-excision after unplanned resection of a soft tissue sarcoma of the extremities and trunk.

Matthias Peiper, Prof., Dr.

55F #10089-Effect of histone deacetylase inhibitor (HDACI) PCI-24781 on chemotherapy-induced apoptosis in multidrug-resistant sarcoma cell lines.

Edwin Choy, MD, PhD

55G #10090-Evaluation of nilotinib (N) in advanced GIST previously treated with imatinib mesylate (IM) and sunitinib (S).

Carolina Cauchi

55H #10091-Measurement of interstitial fluid pressure (IFP) and circulating biomarkers in soft tissue sarcoma (STS): An exploratory phase II clinical and correlative study of sorafenib (SOR) in patients with refractory STS (NCI Protocol 6948).

Chandrajit P. Raut

56A #10092-The GOLD reGISTry: A global observational registry collecting longitudinal data on patients with advanced GIST-Second annual summary.

Matias Chacon

56B #10093-Extraskelatal osteosarcoma: Clinicopathologic features and results of multimodal management.

Nicola Fabbri, MD

56C #10094-Analysis of prognostic factors of pediatric-type sarcomas in adult patients.

Hee Kyung Ahn

56D #10095-Radiological tissue changes and pathological response in localized high-grade soft tissue sarcomas (STS) as predictors of outcome after neoadjuvant treatment with chemoradiotherapy (CRT).

Antonio Lopez-Pousa

56E #10096-Clear cell sarcoma (CCR): Clinical behavior and response to chemotherapy.

Silvia Stacchiotti

56F #10097-A national registry for the off-label use of targeted therapies in patients (pts) with malignant mesenchymal tumors: A retrospective study from the GSF-GETO.

Jacques-Olivier Bay

56G #10098-Systemic therapy in clear cell sarcoma.

Anastasia Constantinidou

Session Title: #215: Predictors of Response to Preoperative Therapy: Where are We?

Session Type: Clinical Science Symposium

Date: Sunday, June 6

Location: N Hall B1

Time: 4:30 PM - 6:00 PM

- Predictors of Response to Preoperative Therapy: Where are We?
William Fraser Symmans, MD
- Predictors of Response to Preoperative Therapy: Where are We?
Antonio C. Wolff, MD, FACP
- Discussion: Preoperative Therapy in Operable Breast Cancer: How, When, and Why?
Gabriel N. Hortobagyi, MD, FACP
- #500-Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: A multicenter, randomized phase II study (GEICAM/2006-03).
Emilio Alba
- #501-Impact of treatment characteristics on response of different breast cancer subtypes: Pooled multilayer analysis of the German neoadjuvant chemotherapy trials.
Gunter Von Minckwitz
- #502-Molecular and genomic predictors of response to single-agent doxorubicin (ADR) versus single-agent docetaxel (DOC) in primary breast cancer (PBC).
Miguel Martin
- #LBA503-Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis.
Herve R. Bonnefoi, MD
- Discussion
Mitchell Dowsett, PhD

Session Title: #10: Aging, Frailty, and Medical Therapy for Colorectal Cancer: Who Should Be Treated and How?

Session Type: Education Session

Date: Sunday, June 6

Location: S404

- Age, frailty, and chemotherapy - data, more data, and more confusion

Daniel J. Sargent, PhD

- Elderly and/ or frail patients with colorectal cancer - a clinician's approach

Richard M. Goldberg, MD

Session Title: #74: Myelodysplastic Syndromes and Elderly Acute Myeloid Leukemia

Session Type: Education Session

Date: Sunday, June 6

Location: E354a

Time: 4:45 PM - 6:00 PM

- Prognostic models in MDS

Guillermo Garcia-Manero, MD

- Beyond supportive care in MDS- growth factors -epigenetic therapies, immunomodulators and novel chemotherapeutic agents.

David Steensma, MD

- Acute Leukemia in the elderly . Who should be treated and how.

Farhad Ravandi Kashani, MD

Session Title: #80: New Technology in Cancer Immune Therapy

Session Type: Education Session

Date: Sunday, June 6

Location: E353

Time: 4:45 PM - 6:00 PM

- T cell engineering for adoptive immunotherapy

Zelig Eshhar, PhD

- Chimeric Immunoreceptor Engineered T-cells

Michel Sadelain, MD, PhD

- Combinatorial immunotherapy

Leisha A. Emens, MD, PhD

Session Title: #82: Nonmelanoma Skin Cancers: New Insights, New Directions

Session Type: Education Session

Date: Sunday, June 6

Location: S406 (Vista Room)

Time: 4:45 PM - 6:00 PM

- Non-melanoma skin cancer in the immunosuppressed patient
Juergen C Becker, MD, PhD
- Merkel cell carcinoma: new biologic insights and management strategies
Paul Nghiem, MD, PhD
- Molecular pathways in basal cell carcinoma and clinical trials
Jean Y Tang, MD, PhD

Session Title: #88: Physical Activity in Cancer Populations: What's New?

Session Type: Education Session

Date: Sunday, June 6

Location: E354b

Time: 4:45 PM - 6:00 PM

- Physical Activity and Cancer: Overview and Implications for Survivorship
Jennifer A. Ligibel, MD
- Randomized trials of exercise in cancer patients: Health-related fitness and patient-reported outcomes
Kerry S. Courneya, PhD
- Exercise Testing and Prescription for Cancer Survivors: Guidelines from the American College of Sports Medicine
Kathryn Schmitz, PhD, MPH

Session Title: #94: Stem Cells in Neuro-oncology

Session Type: Education Session

Date: Sunday, June 6

Location: S100b

Time: 4:45 PM - 6:00 PM

- Stem Cells in Neuro-Oncology: overview
Richard Gilbertson, MD, PhD

- Using Stem Cells to Treat Brain Tumors

Evan Snyder, MD, PhD

Session Title: #99: The Evolution of a Disease: How Does the Changing Epidemiology of Esophagogastric Cancers Affect Treatment Decisions?

Session Type: Education Session

Date: Sunday, June 6

Location: E Hall D1

Time: 4:45 PM - 6:00 PM

- Understanding the evolution in epidemiology of esophago-gastric cancer.

Johanna C. Bendell, MD

- The molecular continuum of Barrett's esophagus to esophagogastric cancer.

Jason L Hornick, MD, PhD

- Using the newest molecular markers in prognosis and risk stratification.

Janusz Jankowski, PsyD

Session Title: #116: Cutaneous B-cell Lymphoma

Session Type: Meet the Professor Session

Date: Sunday, June 6

Location: E451b

Time: 4:45 PM - 6:00 PM

- Cutaneous B-cell Lymphoma

Lynn D. Wilson, MD, MPH

Session Title: #131: Incidental Findings on Imaging in the Patient with Cancer: A Prudent Approach to Evaluation and Management

Session Type: Clinical Problems in Oncology Session

Date: Sunday, June 6

Location: E451a

Time: 4:45 PM - 6:00 PM

- The Incidental Renal Mass: Evaluation and Management in the Cancer Patient

Scott Michael Gilbert, MD, MS

- The Incidental Adrenal Mass: Evaluation and Management in the Cancer Patient

J. Stuart Wolf, Jr., MD

- The Incidental Pulmonary Nodule: Evaluation and Management in the Cancer Patient

David E. Ost, MD

Session Title: #267: B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology

Session Type: Special Session

Date: Sunday, June 6

Location: S100a

Time: 4:45 PM - 6:00 PM

- B.J. Kennedy Award and Lecture for Scientific Excellence in Geriatric Oncology

Harvey Jay Cohen, MD

Session Title: #243: Developmental Therapeutics - Experimental Therapeutics

Session Type: Poster Discussion Session

Date: Sunday, June 6

Location: E Hall D2

Time: 5:00 PM - 6:00 PM

- Developmental Therapeutics - Experimental Therapeutics

Ross A. Soo, MD

- Developmental Therapeutics - Experimental Therapeutics

Patrick Schoffski, MD, MPH

1 #3015-A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors.

Roger B Cohen

2 #3016-Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.

Valentine M Macaulay

3 #3017-A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).

Heather A. Wakelee, MD

4 #3018-Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors.

Igor Puzanov

- Discussion: Interrupting Growth Factor Pathways Cross-Talk: Combinations With Erlotinib

Tomislav Dragovich, MD, PhD

5 #3019-Association of the *hemochromatosis (HFE)* gene with pazopanib-induced transaminase elevations in renal cell carcinoma.

Chun-Fang Xu

6 #3020-Effect of coadministration of statins on neutropenia in a phase I genotype-directed dose-escalation study of irinotecan.

Federico Innocenti

7 #3021-Inherited genetic variation in *EPHA5*, *FGD4*, and *NRDG1* and paclitaxel (P)-induced peripheral neuropathy (PN): Results from a genome-wide association study (GWAS) in CALGB 40101.

Deanna L. Kroetz

8 #3022-Systemic delivery of siRNA via targeted nanoparticles in patients with cancer: Results from a first-in-class phase I clinical trial.

Antoni Ribas, MD

9 #3023-Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors.

Patricia Tresca

10 #3024-A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors.

Alex A. Adjei, MD, PhD

11 #3025-Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer.

Robert C. Newton

12 #3026-Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs).

Emiliano Calvo

13 #3027-A phase I combination study of olaparib (AZD2281; KU-0059436) and cisplatin (C) plus gemcitabine (G) in adults with solid tumors.

Giuseppe Giaccone

- Discussion: Design of early development combination trials

Elizabeth A. Eisenhauer, MD

14 #3028-Final report of phase I clinical, pharmacokinetic (PK), pharmacodynamic (PD) study of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with solid tumors.

Neesha C. Dhani

15 #3029-Utilizing mechanistic PK/PD modeling to simultaneously examine free CCL2, total CCL2, and CNTO 888 serum concentration time data.

Gerald J. Fetterly

16 #3030-A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies.

Irene Brana

17 #3031-Pharmacokinetic (PK) and pharmacodynamic (PD) results from two phase I studies of the investigational selective Aurora A kinase (AAK) inhibitor MLN8237: Exposure-dependent AAK inhibition in human tumors.

Andres Cervantes-Ruiperez

18 #3032-Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies.

Richard R. Furman

19 #3033-Pharmacodynamically guided dose selection of PF-00337210, a VEGFR2 tyrosine kinase (TK) inhibitor, in a phase I study.

Glenn Liu

- Discussion: Applying PK/PD principles to development of anticancer agents.

Jan H. M. Schellens, MD, PhD

Session Title: #248: Gynecologic Cancer

Session Type: Poster Discussion Session

Date: Sunday, June 6

Location: E Arie Crown Theater

Time: 5:00 PM - 6:00 PM

- Gynecologic Cancer

Seiko Diane Yamada, MD

- Gynecologic Cancer

Claire F. Verschraegen, MD

1 #5009-A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.

Todd D. Tillmanns

2 #5010-A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study.

Robert L. Coleman, MD

3 #5011-A phase II, nonrandomized study of nab-paclitaxel plus carboplatin in patients with recurrent platinum-sensitive ovarian or primary peritoneal cancer.

Benedict B. Benigno

4 #5012-Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study.

Andres Poveda

5 #LBA5012b-PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.

R. Wendel Naumann

6 #5014-Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC).

Elisa Gallerani

7 #5015-Immunotherapy with intraperitoneal catumaxomab in patients with advanced ovarian cancer after a complete response to chemotherapy: A phase II study.

Robert W. Holloway

- Discussion: old wines in new bottles.

9 #5017-Clinical characteristics and outcomes of *BRCA*-associated ovarian cancer (OC): Genotype and survival.

Verena Engelstaedter

10 #5018-Breast cancer protein expression as a prognostic marker in sporadic epithelial ovarian cancer (EOC): An NCIC CTG OV.16 correlative study.

Johanne Ingrid Weberpals

11 #5019-Impact of *BRCA1* gene alterations on tumor characteristics and clinical outcome in ovarian cancer (OC) patients.

Desislava Dimitrova

12 #5020-Use of microarray-based comparative genomic hybridization analysis to identify prognostic subgroups of ovarian clear cell carcinomas.

David Shao Peng Tan

13 #5021-A gene expression algorithm for the prediction of platinum sensitivity in ovarian cancer.

James Stuart Ferriss, MD

14 #5022-Use of HE4 expression in plasma to predict operative outcome in patients with ovarian cancer (OC).

Elena Ioana Braicu

- Discussion: Biomarkers in ovarian cancer - forward progress or back to the future?

Michael J. Birrer, MD, PhD

16 #5024-Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases.

Rowena Cabigon Mercado

17 #5025-Impact of microsatellite instability in overall survival of women with endometrial cancer.

Jose Claudio Casali da Rocha, MD, PhD

18 #5026-Evaluation of insulin resistance among endometrial cancer patients.

Jennifer K. Burzawa

19 #5027-Influence of radiation modality and nodal dissection on survival in high-risk early-stage endometrial cancer.

Junzo P. Chino

20 #5028-Adjuvant chemotherapy and chemoradiation following surgery for high-risk endometrial cancer.

Kailash Narayan

21 #5029-A phase II trial of radiotherapy sandwiched between carboplatin and docetaxel for stage III, IV, and recurrent endometrial cancer.

Melissa Ann Geller, MD

- Discussion: Whats new in Endometrial Cancer?

Angeles Alvarez Secord, MD

22 #5030-Treatment outcomes for older women with advanced ovarian cancer: Results from a phase III clinical trial (GOG182).

William P. Tew

23 #5031-Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial.

Jean-Emmanuel Kurtz

24 #5032-Defining clinical and statistical improvement in consolidation single-arm trials in ovarian cancer.

David R. Spriggs, MD

25 #LBA5033-Carboplatin (C) plus paclitaxel (P) versus carboplatin plus pegylated liposomal doxorubicin (PLD) in patients with advanced ovarian cancer (AOC): final analysis of the MITO-2 randomized multicenter trial.

Sandro Pignata

- Discussion: Mining Phase III studies - gold or quicksilver?

Mahesh Parmar, PhD

Session Title: #257: Pediatric Oncology

Session Type: Poster Discussion Session

Date: Sunday, June 6

Location: S504

Time: 5:00 PM - 6:00 PM

- Pediatric Oncology

Maryam Fouladi, MD

- Pediatric Oncology

Rochelle Bagatell, MD

39A #9521-High throughput transcriptome sequencing of pediatric relapsed acute lymphoblastic leukemia (ALL).

Laura E. Hogan

39B #9522-Association of a genetic variant in the *ABCC2* gene with high methotrexate plasma concentrations in pediatric malignancies.

Melanie M. Hagleitner

39F #9523-Biomarkers in the prediction of vincristine metabolism and neuropathy in pediatric acute lymphoblastic leukemia patients.

Amalia S Lehmann, BS

39G #9524-ABC drug transporter gene expression in neuroblastoma.

Samantha Cialfi

39H #9525-Use of loss of function RNA interference screen to evaluate TNK-2 as a factor involved in rhabdomyosarcoma cell growth.

Fernanda Irene Arnaldez

40A #9526-Genetic variants in *MDR1* and *CYP3A5* and vincristine toxicity in children with acute lymphoblastic leukemia.

Dunja Maroeslea W.M. Te Loo

40B #9527-Use of immunoglobulin heavy chain primer pools to assess minimal residual disease/persistent disease (MRD/PD) in children and adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL): A Children's Oncology Group report.

Bruce Shiramizu

40F #9528-Candidate serum biomarkers of doxorubicin-induced cardiotoxicity in pediatric acute lymphoblastic leukemia assessed by nanoparticle-capture mass spectrometry.

Emanuel Petricoin

40G #9529-A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora a kinase: A Children's Oncology Group Phase I Consortium study.

Yael P. Mosse

40H #9530-A pediatric phase I trial and pharmacokinetic study of aflibercept (VEGF Trap): A Children's Oncology Group Phase I Consortium study.

Julie R. Park

41A #9531-A multicenter, first-in-pediatrics phase I study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors.

Lia Gore

41B #9532-Phase I trial of lestaurtinib for children with refractory neuroblastoma (NB): A New Approach to Neuroblastoma Therapy (NANT) Consortium Study.

Jane E. Minturn

41C #9533-Phase II window of irinotecan plus carboplatin in newly diagnosed patients with rhabdomyosarcoma: Results of Memorial Sloan-Kettering Cancer Center (MSKCC) Protocol IRB 03-099.

Leonard H. Wexler

41D #9534-Cisplatin plus pirarubicin chemotherapy and combination ifomide, etoposide, pirarubicin, and carboplatin chemotherapy for hepatoblastoma.

Eiso Hiyama

41E #9535-Phase II trial of pemetrexed in children with refractory solid tumors: A Children's Oncology Group study.

Anne Benedicta Warwick

41F #9536-Safety, kinetics, and outcome following rituximab (R) in combination with FAB chemotherapy in children and adolescents (C+A) with stage III/IV (Group B) and BM+/CNS+ (Group C) mature B-NHL: A Children's Oncology Group report.

Mitchell S. Cairo, MD

41G #9537-A phase II study of bortezomib with ifosfamide and vinorelbine in pediatric patients with refractory/recurrent Hodgkin Disease (HD): A Children's Oncology Group (COG) study.

Terzah M. Horton

41H #9538-Predicting an optimal strategy for insulin-like growth factor 1 (IGF1) signaling interference in Ewing's sarcoma (ES).

Addy C. M. van de Luitgaarden

- Discussion: New agents or combinations in childhood cancers

Frank M. Balis, MD

42A #9539-A pilot study using carboplatin, vincristine and temozolomide for children with progressive/symptomatic low-grade glioma: A Children's Oncology Group (COG) study.

Murali M. Chintagumpala

42B #9540-Phase I study of single-agent perifosine for recurrent pediatric solid tumors.

Oren J Becher

42C #9541-Phase II study of temsirolimus in children with high-grade glioma, neuroblastoma, and rhabdomyosarcoma.

Birgit Geoerger

42D #9542-Hypothalamic/pituitary radiation exposure in low doses on fertility in female childhood cancer survivor study (CCSS) participants.

Daniel M. Green

- Discussion: Advances in CNS therapy

Mark W. Kieran, MD, PhD